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Accumulation of silicone elastomer in patients on regular hemodialysis.
T. Leohapand, A. R. Morley, M. K. Ward, and D. N. S. Kerr.
University of Newcastle upon Tyne, Newcastle upon Tyne, England.
Silicone elastomer has been reported in the liver of patients treated by
regular hemodialysis and associated chronic liver disease has been
attributed to it. Following these reports we have reviewed the sections
taken at autopsy from 78 patients who died between 1964 and 1981 after
treatment by peritoneal (PD) or hemodialysis (HD). All tissue samples
were examined by polarized and phase-contrast microscopy. Silicone
elastomer was identified as phase-contrast positive material in small
giant cells and macrophages. It was found in 29 patients (37%). None
was identified in the six patients treated by PD alone. In those treated
by HD the cumulative incidence rose from 9.5% at 0 to 20 weeks of HD
to 40.3% at 501 to 520 weeks. Elastomer was found in a wide range of
organs: liver 26, spleen 15, lungs 3, lymph nodes 2 patients. Th range
of morphological change in the livers of patients with and without
silicone elastomer was similar, suggesting that this material is not an
important cause of chronic liver disease. Scanning electron microscope
studies of the walls of dialysis pump inserts demonstrate changes
following dialysis which may represent the source of this material.
Chronic liver disease in hemodialysis patients. P. S. Parfrey, F. J.
Paradinas, J. B. O'Driscoll, J. R. Curtis, and P. E. Gower. Charing
Cross Hospital, London, England. At the end of 1981 there were 125
patients on hemodialysis for more than a year, 24 of whom had
developed chronic persistent transaminemia (CPT)-ALT always greater
than 40 s/liter for more than 1 year, and 12 had chronic intermittent
transaminemin (CIT)-ALT sometimes greater than 40 /1iter for more
than 1 year. All subjects were hepatitis B antigen negative. Biopsy
specimens were taken from the liver of 17 patients with CPT and
postmortem samples from four with CIT and seven with normal liver
function. Mean ALT for 1 year prior to biopsy was calculated; serum
ferritin, viral antibodies and HLA haplotypes were measured: and liver
biopsy specimens scored for the degree of inflammation, fibrosis,
refractile particles, and siderosis. Mean ALT was significantly associat-
ed with inflammation score (r = 0.82, P < 0.001), fibrosis score (r =
0.75, P < 0.001) and refractile particle score (r = 0.70, P < 0.001) but
not with siderosis score, serum ferritin, or HLA haplotype. Refractile
particles were observed in all subjects, particularly in a centrilobular
situation and were usually associated with perivenular inflammation
and fibrosis. Refractile particle score was not associated with the
number of years on dialysis. However, inflammation not directly
related to refractile particles was often observed. Chronic liver disease
has occurred in 29% of hemodialysis patients. This is not related to iron
overload or hepatitis B infection but may be partly the result of foreign
material accumulating in the liver. Other unknown agents may also
contribute to liver damage.
Leucopenia, hypokia and complement activation in hemodialysis (HD).
Three unrelated phenomena. S. G. de Vinuesa, M. Resano, J. Luño, C.
Gonzdloz, G. Barril, E. Junco, and F. Valderrdhano. Servicio Dc
Nefrologia, Hospital Provincial, Madrid, Spain, To elucidate the
pathogenesis of hemodialysis induced leucopenia and hypoxemia, we
studied the effects on oxygen arterial pressure (Pa02, Technicon blood
gases analyser), leucocyte count (Counter Coulter) and complement
(total hemolytic complement, activity of alternative pathway, C3, C4,
and B factor by imniunohemolysis or immunodiffusion) in eight regular
hemodialysis patients sequentially submitted to different dialysis proce-
dures: HD with acetate as a buffer (AHD), cuprophan membrane (CP)
and poliacrilonitrile membrane (PAN);; HD with bicarbonate (BHD);
hemofiltration (HF) with acetate fluid, and acetate cellulose membrane,
and ultrafiltration (UF) with PAN membrane. With the use of CP
membrane, we observed a marked leucopenia 15' after the start (P <
0.001). At the same time the total complement level descended 32' (P <
0.01). In HF with acetate cellulose membrane and HD with PAN the
decrease in the leucocyte count was less marked, but both procedures
induced very significant complement drop (38 and 30%, respectively).
However using PAN in UF, the complement is not activated, but there
is a mild significant leucopenia. The alternative pathway, C3 and B
levels suffered a parallel decrease showing that complement is activated
through the alternative pathway. Significant hypoxemia only appears in
AHD even with PAN. From these data, we can infer that the leucopenia
during dialysis depends on the membrane used and is not the cause of
the hypoxia, which may be related to the use of acetate. The comple-
ment activation is not related with the level of leucopenia, doesn't
appear in UF, and can be considered an independent phenomenon.
Does arteriosclerosis caused by dialysis limit this treatment? J. Kindler,
H. G. Sieberth, W. M. Gldckner, H. Vlaho, R. Peizer, and G. Hahn.
Medical Faculty of Aachen, Department of Internal Medicine II,
Aachen, Germany. The mortality from cardiovascular complications in
RDT-Programme is quoted by various authors as 45 to 60%, and is
stated to increase as the length of time on dialysis. In our own patients,
we could not confirm these data. The mortality among 88 patients who
had been on dialysis for more than 5 years (up to 17 years max.) was
substantially lower than the mortality of patients during the first 5 years
on dialysis.
N
3
Age
(years)
Length of treat-
ment (months)
Number of
deaths
Cardiovascular
cause of death
Cerebrovascular
cause of death
Total Patients on Patients on
dialysis for dialysis for
<5 years >5 years
332
147
185
x = 41.9
(range 8—75)
x = 39.06
(range 0.03—181)
244
107
137
x = 44.28
(range 13—75)
x = 20.54
(range 0.03—59)
88
40
48
x = 35.47
(range 8—69)
x = 90.42
(range 60—181)
135 (41%) 121 (49%) 14 (16%)
41
18%
17
38
22%
16
3
5%
1
The analysis of data on our patients showed that the mortality under a
dialysis regime is primarily attributable to the vascular damage caused
by high blood pressure and the unfavorable VLDL/HLDL quotient in
the beginning of the treatment. The treatment of the patient before he is
accepted on dialysis seems therefore to be the determining factor in the
prognosis for him during dialysis. In the first 6 months on dialysis, 77%
of all patients demonstrated hyperlipidemia. This percentage had
dropped to 17% for those on dialysis for more than 30 months. The
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mortality of patients with high VLDL/HLDL quotient was higher than
in a control group of dialysis patients with a low quotient.
Ultrashort hemodiafiltration: Long-term efficiency and hemodynamic
tolerance. V. Wizemann, and G. Schütterle. Zentrum far Innere Medi-
zin, Federal Republic of Germany. Fifteen patients have been treated
by hemodiafiltration (HDF) 3 x 2 hr/week for more than 1 year.
Hemodiafilters with high diffusive clearances as well as a device with
automatic fluid replacement and volume controlled ultrafiltration have
been used. Compared to the preceeding hemodialysis (HD) period (3 x
4 hr/week) biochemical parameters did not deteriorate despite a reduc-
tion of treatment time by 50%. Fluid removal (1.5 kg/hr) was well
tolerated during HDF. In a prospective study the incidence of dialysis-
associated symptoms was lower during HDF than during HD with
controlled ultrafiltration. Hemodynamically HDF caused an adequate,
norepinephrine-induced counterregulation of peripheral resistance due
to fluid removal. It is concluded that HDF provides a superior efficien-
cy than hemodiafiltration as well as a comparable hemodynamic
tolerance.
Discontinuation of chronic hemodialysis after control of arterial hyper-
tension: Long-term follow-up. J. P. Wauters and H. R. Brunner,
Department of Medicine, University Hospital, Lausanne, Switzerland.
Among 200 patients on chronic hemodialysis (HD) for endstage renal
disease, effective long-term antihypertensive therapy allowed discon-
tinuation of HD in five of them. These patients, three females and two
males, aged 28 to 64 yrs, were suffering from nephroangiosclerosis (2),
glomerulonephritis, scleroderma or interstitial nephritis, respectively.
All had symptoms of renal disease or hypertension for at least 1 year
when they had to start HD with an average blood pressure of 245/152
38/19 mm Hg (mean 1 SD), stage IV retinopathy and serum creatinine
of 1248 164 j.mole/liter. After a mean of 11 months (range, Ito 30) of
strict blood pressure control, renal function improved to such a degree
that HD could be discontinued. Mean serum creatinine was at 500 222
ismoles/liter. In the three patients in whom blood pressure remained
under control and no renal complication occurred, blood pressure is
now at 150/90, 135/95, and 120/90 mm Hg and serum creatinine at 275,
180, and 125 moles/liter after 47, 60, and 38 months, respectively, of
HD discontinuation. One of these patients has even carried a normal
pregnancy to full-term. In one patient, subsequently noncompliant,
blood pressure rose to 2 10/120 mm Hg and HD had to be resumed after
31 months. In the last patient, an episode of acute pyelonephritis made a
return to HD imperative after 8 months interruption. These two patients
have again been on HD for 15 and 19 months. Conclusion: Strict blood
pressure control in patients with endstage renal disease may have a
prolonged beneficial effect on renal function. Therefore, bilateral
nephrectomy should be avoided.
Continuous ambulatory peritoneal dialysis (CAPD) and cellular immu-
nity. A. Giangrande, P. Cantti, A. Limido, D. De Francesco, V.
Malacrida. Nephrology and Dialysis Unit, Department of Clinical
Biochemistry, General Provincial Hospital, Busto Arsizio-Italy. It has
been suggested that inhibitory factors retained in the serum of uremic
patients may affect cell-mediated immunity. This hypothesis has been
therefore evaluated with E-Rosettes (E) test in 49 uremic patients: 22
treated by hemodialysis, 16 by intermittent peritoneal dialysis, and II
by CAPD. In 25 out of 38 patients on RDT, E were reduced. The same
rate was observed at the beginning of therapy in CAPD patients, but it
was followed by a progressive rise up to a normal value after 3 to 6
months of treatment. To identify the inhibitor factor removed by
CAPD, peritoneal dialysis fluids were ultrafiltered through Amicon
membranes with different cut-off and tested with lymphocytes of
healthy donors. The fraction with a molecular weight of less than 500
daitons caused the greatest inhibitory effect on E number (53%). When
this fraction was extracted with chloroform, a significant increase of E
(P < 0.01) was observed. Our results suggest that CAPD removes low
molecular weight polar lipid substances which inhibit the T lymphocyte
functions.
An integrated program of hemodialysis and peritoneal dialysis (HDPD):
A single 2 liters exchange per night plus hemodialysis (HD) every five
days. V. Cambi, G. Garini, L. Occhialini, and D. Tagliavini. Nephrolo-
gy, University of Parma, Italy. Critical problems of CAPD: (1) peritoni-
tis, (2) protein loss, (3) intra-abdominal pressure, and of HD: vascular
instability, can be rationally faced by an integrated intra- and extracor-
poreal approach. One two-liter exchange per night reduces (1) and (2)
and eliminates (3). HD destabilizing hemodynamic factors: fluid excess,
K and acid-base swinging would be better controlled. The steady state
pre-HD BUN levels are predicted by means of a single pool mathemati-
cal model. Parameters: body weight = 70 kg; BUN distribution volume
= 42 liters; BUN generation rate mg/mm (G); residual renal function ml/
mm (RRF); BUN dialyzer clearance = 150 mI/mm; dialysis time: 4 hr.
BUN 50 mg% RRF = 3 G 3.9 HD every 4 days
BUN 107 mg% RRF 0 G = 5.0 HD every 6 days
In five chronic patients hemodialyzed every 5 days, pre-HD BUN
levels confirmed the mathematical prediction. Weight gain was limited
to + 1—2% body weight, HCO3 20 to 22, K 4.5 to 5.5 mEq/liter.
Appropriate glucose concentrations allowed net UF of 400 to 900 ml,
without changes in lipid profile. Protein loss: 1 to 2 g/liter. Conclusion:
HDPD appears metabolically adequate without CAPD disadvantages.
Daily correction of fluid excess, K and acid-base abnormalities, prepare
the patient to a well balanced, highly tolerated HD session.
Peritonitis (PE) prevention in CAPD: Long-term efficacy of a bacterio-
logical filter. A. Slingeneyer and C. Mion. Department of Nephrology,
University Hospital, Montpellier, France. The high incidence of PE
remains the hallmark of CAPD, the best series reporting a peritoneal
infection rate (PIR) of Ito 1.2 PE/patient/year. This frequent complica-
tion is due to the use of an open circuit for dialysate infusion with 3 to 5
daily exchanges. Since starting CAPD in September 1978, we devel-
oped a technique using an in-line microbiological filter on the dialysate
infusion line, hoping that the filter should reduce PIR by preventing the
access to the peritoneal cavity of bacteria contaminating the dialysate at
the time of bag exchange or during storage. From September 1978 to
February 1982, 123 patients (84 males, 59 females; age SD = 56.7
12) were treated on CAPD for l month with this device. During a
cumulative treatment duration of 137.3 years (mean/pt = 1. 1 0.8
years), 87 PE occurred in 52 patients (42%); this corresponds to an
overall incidence of 0.63 PE/patient/year, or 1 PE every 1.57 patient
treatment year. To confirm the long-term efficacy of the filter, the
actuarial risk (AR) of having a PE was computed using the life-table
method in three groups of patients identified according to their time of
admission on CAPD: P1 = 46 patients, 1978 to 1979; P2 = 36 patients,
1979 to 1980; P3 = 30 patients, 1980 to 1981. From start of CAPD, the
time necessary to observe a PE in 50% of patients (50% AR) was 11 and
18 months, respectively, during P1 and P2; during P3, the % AR at 16
months reached 40%. In terms of PE/patient/year, the PIR during P1,
P2, and P3 was 0.78, 0.56, and 0.58, respectively. This persistingly low
PE incidence observed in a 3-year period in a large group of unselected
patients is best explained by the use of the filter and let us believe that
improved technology for CAPD connection including microbiological
filtration will lower CAPD PIR to the same low levels observed with
closed circuit IPD (PIR = 0.17 per patient per year).
Evolution of residual renal function in patients undergoing mainte-
nance hemodialysis or continuous ambulatory peritoneal dialysis. A
comparative study. J. Rottembourg, B. Issad, P. Degoulet, F. Aimé, B.
Gueffaf, andM. Legrain. Department of Nephrology, HôpitalLa Pitié,
Paris, France. Even low persisting residual renal function, expressed
by glomerular filtration rate (GFR) is a major contributing factor to the
well being of patients on dialysis therapy. Since continuous ambulatory
peritoneal dialysis (CAPD) is an alternative treatment to maintenance
hemodialysis (MH), a comparative retrospective study to appreciate the
values of residual renal function on both MH and CAPD was set up.
Fifty patients studied over a period of 18 months were divided in two
matched groups: Group 1: 25 patients (15 males, 10 females), mean age
57.2 13.2 years, mean body weight 62.0 10.7 kg were treated by
MH using a three dialysis sessions per week schedule. Group 2: 25
patients (15 males, 10 females) mean age 61.6 14.6 years, mean body
weight 63.2 11.1 kg were treated by CAPD using a four bags per day
schedule. There were no statistical differences between the two groups
according to sex, age, body weight, and primary renal disease. On both
techniques at a 6-month interval, residual creatinine clearance was were
measured on a 24-hr period, the day before dialysis and blood samples
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were drawn immediately before the session on MH, at any day of the
week on CAPD. Results (mi/mm) appear on the following table:
Months 0 6 12 18
Gi MH 4.3 2.3 2.7 1.8 2.1 1.5 1.3 1.2
Gil CAPD 4.4 2.4
P = NS
4.4 2.2
P < 0.04
3.8
P
2.8
0.01
4.0 2.3
P < 0.001
At 6 months and thereafter the GFR is significantly much higher in the
group of patients treated by CAPD. In this group the residual renal
function did not deteriorate during the 18 months of observation and
stabilized around 4.0 mI/mm.
Cadaver kidney transplantation across a blood group barrier, "A2-
kidneys" to "0" recipients. H. Brynger, B. Samuelsson, I. Blohmé, and
L. Sandberg. Department of Surgery I, and Bloodcentre, Sahigren's
Hospital, Gothenburg, Sweden. Since 1960 ABO-compatibility be-
tween donor and recipient has been considered a prerequisite for
successful renal transplantation. In ABO-incompatible grafts, quick
rejections occurring between a few hours to several days after grafting
have been reported, with intravascular hemagglutination of small
vessels of the graft as the dominant histological feature. Based on the
fact that in blood group A2-donors (subgroup of blood group A) the A
determinants of the erythrocytes are quantitatively fewer and A2
erythrocytes are less susceptible to anti-A-isoagglutinines, we decided
to try to transplant A2-kidneys in 0 recipients. The outcome of this
clinical trial is the aim of the present communication. Between 1974 and
1981, six primary and one secondary cadaveric grafts from A2-donors
were transplanted into seven 0 recipients. Two of the grafts were lost
due to non-immunological causes, one early arterial thrombosis and one
infection with acute arterial bleeding after 10 days of excellent graft
function. All the remaining five grafts initially normalized the
creatinine; one kidney was removed after 35 days due to an irreversible
acute cellular rejection. The remaining four grafts all had long-time
function with the longest current survival of almost 4 years. The
outcome of this small series indicates that transplantation of blood
group A2-kidney into 0-recipients is feasible and may lead to long-term
function. No hyperacute or accelerated rejection was seen.
Influence of Lewis and other blood group systems in cadaver kidney
transplantation. V. Lenhard, B. Hansen, D. Roelcke, K. Dreikorn, P.
Wernet, H. Bockhorn, W. Fassbinder, R. F. Fetta, H. Wilms, B.
Gumbel, F. W. Albert, R. W. Ewald, I. Sprenger-Klasen, and S. F.
Goldmann. Heidelberg, Tübingen, Frankfurt, Freiburg, Kaiserslau-
tern, Mannheim, Ulm, Federal Republic of Germany. The objective of
this prospective multicentric study was to analyze the separate influ-
ence of Lewis and other blood group systems on kidney graft survival.
In addition, the effect of combined red cell incompatibilities was
studied. In 167 first cadaver kidney recipients and their respective
donors the blood groups ABO, Rhesus, Lewis, MNSs, P, Kell, and
Duffy were determined by the usual hemagglutination technique. Com-
patibility in each system was defined as presence of a given antigen in
donor and recipient. Combinations in which the donor and the recipient
had different antigens were considered incompatible. Graft survival
rates were calculated by actuarial methods, statistical significances
were computed by the log-rank test. The overall graft survival was
61.4% at 1 year. Out of the blood group systems studied, only the Lewis
compatibility resulted in a significant improvement of graft prognosis.
Whereas 1-year graft survival of Lewis-compatible grafts was 67.4%,
Lewis-incompatible grafts functioned only in 52.7% (P 0.02; 14.7%
difference at 1 year). The other blood groups, namely ABO, Rh, MNSs,
P, Kk, and Fy showed no significant effect of graft outcome. However,
the simultaneous presence of several red cell incompatibilities led to
decreased survival rates. Grafts with more than four incompatibilities
survived only in 50.9% as compared to 69.3% of transplants with less
than four incompatibilities (P < 0.01; 18.4% difference at 1 year). When
the Lewis system was excluded from analysis, the difference of I-year
graft survival was reduced to only 5.9%. These data indicate that
cumulative red cell incompatibilities have an unfavorable effect on
cadaver graft survival. Out of the different blood groups, the Lewis
system is of major importance.
Role of minor histocompatibility antigens in HLA identical renal
allografts. J. B. Dossetor, and T. Kovithavongs. Department of Medi-
cine, University of Alberta, Edmonton, Alberta, Canada. It is widely
assumed that effector T cells are directed at HLA-ABC antigens of a
graft. Similar specificity would be expected in suppressor cells generat-
ed after transplantation. That this is not necessarily so is shown in HLA
identical grafts. In five such situations, where there was no rejection,
suppressor cells were shown to have donor specificity when tested in
vitro by the ability of post-transplant recipient cells (R + m) to suppress
donor induction of cytotoxic cells when added to an MLC where donor
cells (Dm) were stimulating unrelated third party lymphocytes (X) in the
MLC-CML system. The ratio for X:Dm:R + m in MLC was
1:1.25:0.25; E/T ratio in CML was 40:1. In studies of four of five HLA
identical pairs, with clear-cut rejection episodes, in vivo generated
cytotoxic cells were detected in recipient PBL by direct lymphocyte
mediated cytotoxicity, LMC. The activity of these cells had a close
temporal relationship to rejection episodes. The only patient to lose a
renal graft by rejection in this group also was infected inadvertently
with hepatitis B virus by her brother's kidney. LMC positivity closely
followed the rejection course and the Zinkernagel phenomenon might
be postulated in this instance. On analysis for A2 or A2 B7 sharing in
female LD recipients of male kidneys a significant increase in rejection
activity was also noted (two of two, male to female, vs. zero of five,
female to female and zero of three, female to male) thus raising the
possibility that H-Y may be one of the alloantigens responsible. Both
sets of data serve to emphasize the non-HLA factors which operate in
clinical renal allografting.
Transplant survival after HLA-A- and 13-matched blood transfusions.
M. J. Nubé, G. G. Perszjn, M. W. Kaiff, A. van Es, J. de Graeff, andJ.
J. van Rood. University Hospital, Leiden, Holland. Twenty nontrans-
fused dialysis patients received a limited number of HLA-A- and B-
matched (identical of compatible) pretranspiant blood transfusions. To
date 15 of them received a primary cadaveric kidney graft under the
auspices of Eurotransplant. Transplant survival at one year is 87% and
patient survival 100%. Patients who received blood transfusions from
random blood bank donors and who were transplanted in the same
center just before and after the protocol group patients, served as a
control group. Transplant survival at 1 year is 76% and patient survival
85%. A poor graft outcome was correlated significantly with the
presence of pretranspiant lymphocytotoxic antibodies with specificities
for HLA-A- and B. The results of our study suggested that the risk of
the formation of these antibodies can be reduced after HLA-A- and B-
matched blood transfusions. Our data indicate that optimal graft and
patient survival can be obtained after pretransplant HLA-A- and B-
matched blood transfusions. The risk of a prolonged dialysis time as a
result of sensitization will be as small as possible.
Influence of blood transfusions (BT) on lymphocyte reactivity in
humans. D. Klatzmann, J. C. Gluckman, C. Foucault, J. Bedrossian,
U. Azogba, E. Brisson, M. Haguet, and M. Legrain. Service de
Nephrologie, UER Pitie-Salpetriere, Paris, France. To investigate the
mechanism of the beneficial effect of prior BT on kidney graft survival,
we havç analyzed the influence of three planned packed erythrocytes
BT, given at monthly intervals on lymphocyte reactivity in humans.
Fifteen previously nontransfused prospective kidney graft recipients,
five of whom not yet treated by dialysis, have been studied. Lympho-
cytes collected sequentially before and after each BT were cryopre-
served and all samples from a given patient were tested in a single
retrospective experiment to eliminate test-to-test variations. A marked
and significant (P < 0.01) decrease in MLC to the blood donor's, as to
other unrelated cells, was observed as early as 10 days after the first BT
in seven patients. This effect waned but it was boosted after each
additional BT and it still existed 90 days after the third in four patients.
Two patients showed a similar prolonged and nonspecific reduction but
it appeared after the second or the third BT. The remaining patients had
only a transient decrease, but they had otherwise normal or even
increased MLC reactivity. Neither the original kidney disease, nor
whether patients were treated by dialysis, nor variations of plasma
creatinin could be related to these MLC reductions. Modifications of
the responses to PHA or soluble antigens were also noted, but they
could not be linked to BT. When mixed in three cell experiments, most
of the lymphocyte suspensions whose MLC was reduced after BT could
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inhibit the response of autologous cells taken before BT. These results
indicate that nonspecific suppression to allogeneic cells can be generat-
ed in vivo by BT.
B lymphocyte antibodies associated with successful renal transplanta-
tion and successful pregnancy. D. A. Power, A. MacLeod, R. J. Mason,
K. N. Stewart, G. Shewan, N. Edward, and G. R. D. Catto. Depart-
ment of Medicine, University of Aberdeen and Blood Transfusion
Service, Aberdeen Royal Infirmary, Aberdeen, Scotland. We have
shown that renal allograft survival was significantly improved when
noncytotoxic Fc receptor blocking antibodies were present in recipient
sera prior to transplantation. Using the erythrocyte antibody inhibition
assay (EAT) with panels of specific donor, normal, and leukemic B
lymphocytes as targets we found (1) 13 out of 15 grafts with but only 11
out of 25 grafts without antidonor EAT survived one year (P < 0.02); (2)
18 out of 23 grafts with but only 12 out of 27 without EAT against the
normal B cell panel survived 1 year (P < 0.05) and (3) 21 out of 26 grafts
with but only 9 out of 24 grafts without anti-CLL panel EAT survived I
year (P < 0.005). These antibodies were not directed to HLA-A, B, or
DR antigens. We now present evidence that such antibodies are
generated by blood transfusion and that similar antibodies are associat-
ed with successful human pregnancy. Tn 12 patients transfused with at
least 5 U of whole blood, 7 out of 12 developed EAT antibodies directed
to leukemic B cells. EAT antibodies were detected in 7 out of 11 women
during the first trimester of a normal first pregnancy, but in none of nine
women at the time of a spontaneous abortion. The mean level of EAT
for the normal pregnant women was 33.5 12.5% and 5.4 7.0% for
the women who aborted (P < 0.001). Family studies have shown that
this activity is linked to the HLA gene complex. These data suggest that
noncytotoxic Fc receptor blocking antibodies directed against MHC-
linked antigens are associated with specific abrogation of the allogeneic
response.
Radiolabelled platelets and prostacyclin in diagnosis and treatment of
transplant rejection. C. Leithner, H. Sinzinger, M. Schwarz, and E.
Pohanka. Second Department of Internal Medicine, University of
Vienna School of Medicine, Vienna, Austria. Platelet deposition in the
transplant plays a pivotal role in graft rejection. Therefore autologous
Ill-Indium labelled platelets were weekly injected into 85 transplant
patients. Under a gamma camera the graft platelet trapping was
determined thrice daily, by calculation of a platelet uptake index (PUT).
The 85 patients were collected in three groups, namely early post-
transplant period, histologically proved chronic rejection, and long-
term good and stable grafts. PUT increased in acute rejection from 1.13
0.11 to T.74 0.17 and decreased again when rejection was
reversible. In chronic rejection PUT was significantly higher (1.33
0.15) than in long-term stable grafts (1.08 0.13). The calculated
platelet t/2 supported these findings. The platelet scan was a valuable
tool for diagnosis of transplant rejection. Prostacyclin infusions were
applied in six patients of acute rejection and 12 of chronic rejection. In
the majority of patients an improval of transplant function and a
decreased platelet trapping could be demonstrated. Prostacyclin seems
to enrich the therapeutic possibilities of rejection treatment. However,
the question, whether or not this benefit will sustain, is open.
Acute vascular rejection treated by plasma exchange. W. Fassbinder,
W. Ernst, H. J. Stutte, E. Scheuermann, U. Frei, and W. Schoeppe.
Departments of Nephrology and Pathology, University Hospital,
Frankfurt, Federal Republic of Germany. Since acute vascular rejec-
tion (AVR) usually does not respond to steroid pulse therapy, it remains
a main cause of graft failure in human cadaveric transplantation. Plasma
exchange (PE) has been considered occasionally in such patients. We
treated 11 episodes of steroid resistant rejection by PE in nine patients.
All patients showed a progressive loss of graft function despite methyl-
prednisolone therapy. Mean dosage (±sD) 3.3 1.4 g/patient. Mean
creatinine prior to rejection was 1.9 1.7 mg/dl and rose to 4.0 2.1
mg/dl. Biopsies were obtained in eight patients. Histological examina-
tion shows in all cases myointimal proliferations of vessels as a distinct
sign of AVR. PE was performed using cellulose-acetate membrane
hollow fiber plasma filters. Six PE, usually 3/week, were performed in
each patient. Per treatment 5 liters of plasma were filtered and
simultaneously replaced by 3.5% albumin-Ringer-lactate-solution. Af-
ter each PE 20g TgG were substituted intravenously. No technical
problems were encountered. All patients are still alive today. Coincid-
ing with PE a prompt improvement of graft function occurred. One
week after the last PE creatinine had dropped significantly (P < 0.001)
to 2.5 1.0 mg/dl. In two patients a second series of PE was necessary,
because AVR recurred. In eight of nine patients treated by PE graft
function could be preserved; only one graft was lost due to irreversible
rejection. Six patients have been observed after PE for >6 months and
four for >12 months; they show no signs of active rejection. Our data
indicate that the poor prognosis of AVR may be improved by PE. Since
PE is a simple and safe procedure, it should be considered the treatment
of choice whenever AVR is diagnosed or suspected.
Plasma prednisolone levels and kinetics in renal transplant patients. W.
E. Nelson, H. Delargy, D. Temple, C. C. Doherty, M. G. McGeown,
andf. F. Douglas. Renal Unit, Belfast City Hospital, Northern Ireland.
Steroid side effects remain one of the major problems in organ trans-
plantation. Plasma prednisolone levels were estimated by high perform-
ance liquid chromatography in 27 renal transplant (RT) patients and
four normal subjects to determine how the range of levels and the
prednisolone kinetics related to dosage, renal function, and side effects.
Prednisolone dosage varied between 8 and 200 mg daily. Peak plasma
levels ranged from 244 ng/ml to 1219 ng/ml and time to peak levels from
0.5 to 4 hr. There was considerable patient variation in peak levels, area
under curve, half life and plasma clearance of prednisolone; this
variation did not correlate with dosage of prednisolone or renal func-
tion. Seven subjects had more than one series with satisfactory repro-
ducibility of results. In three RT patients with steroid-induced glucose
intolerance, the mean plasma prednisolone half life (PPHL) was signifi-
cantly longer compared with normoglycemic RT patients (6.27 vs. 3.27
hr, P < 0.005), and the latter group did not differ significantly from
normal controls (3.27 vs. 3.21 hr, P < 0.005). Of six cushingoid RT
patients, three had poor renal function (GFR 10 mI/mm) and
significant prolongation of PPHL (mean 6.27 vs. 3.21 hr, P <0.005); the
remaining three had stable function (GFR 20 ml/min) and normal
PPHL (mean 3.81 vs. 3.21 hr, P > 0.9). The results show marked
variation of oral prednisolone disposition in RT patients and suggest
steroid toxicity may be related to altered pharmacokinetics. Plasma
prednisolone levels may be useful in tailoring therapy.
Reduced prednisolone bioavailability during rifampicin treatment. H.
Bergrem and 0. K. Refvem (Introduced by P. Fauchald). Medical
Department B, Rikshospitalet, National University Hospital, Oslo,
Norway. Prednisolone pharmacokinetics and protein-binding were
studied in seven subjects before and after 3 weeks' rifampicin treatment
to elucidate the enzyme-inducing effect of rifampicin on prednisolone
disposition. Prednisolone concentrations were measured by a specific
radioimmunoassay and protein-binding by equilibrium dialysis. The
elimination half-time for prednisolone fell by 44.8% 8.0 (P < 0.01),
the area under the time-concentration curve by 47.5% 7.3 (P < 0.01),
and the AUC of nonprotein-bound drug by 56.5% 9.8 (P < 0.01). The
total body clearance of prednisolone increased by 90.8% 26.2 (P <
0.01), but the volume of distribution was unchanged. The reduction in
AUC of nonprotein-bound prednisolone was greater than for total
prednisolone because of nonlinear protein-binding of prednisolone (P <
0.05). Many transplant recipients with tuberculosis will be treated with
rifampicin. The prednisolone dose should be doubled and the dosage
interval shortened to obtain the same bioavailability of prednisolone if
rifampicin is given concomitantly.
Cytomegalovirus (CMV) infection in renal allograft recipients. A
prospective study in 50 patients. G. Mourad, G. Ruiz, G. Chong, M.
Pouliquen, J. Mandin, and C. Mion. Departments of Nephrology and
Microbiology, University Hospital, Montpellier, France. Since January
1980, CMV infection was studied prospectively in 50 cadaver-allograft-
recipients. Tmmunosuppression included low-dose prednisolone (P),
azathioprine (Az), and antilymphocyte globulins (ALG). Serum for
CMV complement-fixing (CF) and immuno-enzymatic (ELTSA) tests
was obtained prior to transplantation (T), weekly during the first month,
monthly thereafter. Viral cultures and serologic tests were performed
twice weekly if fever and/or rejection occurred. Prior to T, detection of
CMV was more sensitive with ELISA (35 patients, 70%) than with CF
(15 patients, 30%). According to ELISA, cultures and clinical picture,
three groups of patients were identified: group 1(17 patients)—ELISA
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fourfold (x4) increase and/or CMV isolation with clinical symptoms:
CMV disease (CMV-D); group 2 (9 patients)—isolated ELISA (x4):
CMV reinfection (CMV-R—; group 3 (24 patients)—non CMV-R nor
CMV-D. In group 1, there were eight primo-infections and nine
reactivations; symptomatology included fever (13), fatigue (7), rigors
(6), leucopenia (10), and liver dysfunction (9); severe manifestations
included acute pancreatitis (1), meningitis (1), and pneumonia (2). As
soon as CMV-D was diagnosed, Az was stopped and P reduced to 0.5
mg/kg/day; graft removal for rejection was necessary in I patient;
reversible rejection occurred in three patients, 2 to 7 days before CMV-
D; recovery was observed in all patients with normal (ten patients) or
deteriorated (5 patients) renal function. In group 2, irreversible rejec-
tion occurred in one patient and chronic rejection in two during the
course of CMV-R. There was no death in any group. Our results
confirm the high incidence of CMV infection in transplant patients;
reduced immunosuppression and early Az withdrawal prevent lethal
cases.
Prevalence and causes of hypertension in long-term surviving trans-
plant patients. M. Wauthier, P. Vereerstraeten, Y. Pirson, C. Tons-
saint, G. P. J. Alexandre, P. Kinnaert, H. Van Geertruyden, and C. van
Ypersele. Université Catholique de Lou vain, Cliniques Universitaires
St-Luc, Bruxelles, Université Ljbre de Bruxelles Hôpital Erasme et
Hôpital Brugmann, Bruxelles, Belgium. The pool of long-term surviv-
ing renal transplant recipients enlarges continuously. This aging popula-
tion develops several complications potentially more critical for its
survival than graft tolerance. In this study we analyze the prevalence,
etiology, and consequences of hypertension in 100 patients followed for
at least 7 years after transplantation. Prevalence of hypertension (HT)
(diastolic blood pressure DBP 90 mm Hg) remains stable, around
55%, from 1 up to 11 years post-transplant. Approximately 50% of the
HT patients have a DBP 100 mm Hg. Age, sex, graft origin, or
prednisolone dosage were not related to HT. By contrast, body weight
was higher in HT patients and the weight gain observed over 7 years
was higher (P < 0.05) in HT than in normotensive (NT) patients.
Prevalence of HT was higher (P < 0.01) in non-nephrectomized (65%)
than in binephrectomized (50%) patients (P < 0.01). Serum creatinine
increment during the first 7 years was higher (P < 0.01) in HT than in
NT. No renal artery stenosis was observed in this group. The incidence
of serious cardiovascular complications during the 7-year follow-up was
four times higher in the HT group (NS). We conclude that the
prevalence of HT is high and renlains stable up to 11 years post
transplantation. in these long-term survivors HT is related mainly to the
recipient's native kidneys and to altered graft function.
Osteomalacia in CRF before dialysis. F. Mora-Palma, H. A. Ellis, D.
B. Cook, M. K. Ward and D. N. S. Kerr. University of Newcastle upon
Tyne, Newcastle upon Tyne, England. OM affects only a minority of
patients before dialysis; its etiology is uncertain but theories include
prolonged uremia, acidosis, and subclinical vitamin D deficiency. To
test these theories we have compared 50 patients who had OM on bone
biopsy before dialysis, all in association with osteitis fibrosa (OF), and a
control series with pure OF. Three factors were significantly associated
with OM. (1) Primary renal disease: Those affecting medulla were over-
represented in the OM group: chronic pyelonephritis 32%, obstruction
18%, analgesic nephropathy 8%, while GN (6%) was under-represent-
ed. (2) Acidosis: Plasma bicarbonate was below 15 mmoles/liter in 62%
of the OM group vs. 25% of the pure OF group. (3) Hypocalcemia:
Serum calcium was below 2 mmoles/liter in 74% of the OM group vs.
21% of the pure OF group. On the other hand, prolonged uremia,
plasma phosphate, and vitamin D seemed less important. Known
duration of uremia averaged 75 months in the OM group vs. 68 months
in the pure OF group. No patient had hypophosphatemia. Of the 12 with
OM in whom serum 25(OH)D was measured, nine had normal levels,
two had nephrotic syndrome and one had Crohn's disease. We con-
clude that pre-dialysis OM is strongly associated with medullary
disease, acidosis, and hypocalcemia.
Efficacy of various treatment modalities on aluminium-associated bone
disease (AABD). B. Ihle, M. Buchanan, B. Stevens, G. Becker, and P.
Kincaid-Smith. Department of Nephrology, Royal Melbourne Hospital
and R.M.I.T. Melbourne, Australia. In 1981, we reported the use of a
specific histochemical (HC) stain for the purpose of identifying patients
with AABD. Only a successful renal transplant (RT) is of benefit for this
condition. Desferrioxamine (DFO) has also been shown to decrease
plasma [Al3j, but the effect at a tissue level has not been reported
previously. In this study we compared the effect of a successful RT (N
= 4) to the effect of 6 monthly DFO treatment (N = 4) in patients on
chronic HD, with bone symptoms in all. Iliac crest bone samples were
obtained prior to RT and DFO and 6 months post-therapy. All eight
patients showed the typical histological picture of AABD (positive HC
stain, increased osteoid, lack of osteoblasts, absence of hyperparathy-
roid changes, inability to label with tetracycline). Bone [Al3] were
assayed by graphite furnace AAS. Histomorphetics were carried out
using a Hewlett-Packard 9874A digitizer. In both groups there was a
>50% reduction in [Al3-] in bone. The HC stain for Al3 became less
distinct and showed staining within the bone matrix. Total bone
increased and osteoid (% total bone and % total surface) decreased
significantly. The osteoid surface covered with osteoblasts increased.
Bone apposition rate also increased markedly. Those treated with DFO
showed greater osteoclast count than those treated with RT (P < 0.01).
Treatment with RT showed greater normalization of bone histology. All
patients, however, had dramatic subjective improvement. We suggest
that DFO is an alternative treatment modality in patients with AABD
who are not suitable for RT, and progress can be monitored easily using
this simple HC stain.
Treatment of fracturing renal osteodystrophy by desferrioxamine. P.
Ackrill, J. P. Day, F. M. Garstang, K. C. Hodge, P. Metcalfe, K. Hill,
A. J. Ralston, J. Ball, and J. Denton. Departments of Chemistry and
Rheumatology, Manchester University and Washington Hospital,
Manchester, England. The effects of aluminium removal by Desferriox-
amine has been studied over a two-year period in three long-term
hemodialysis patients with fracturing renal osteodystrophy. The apatite(trabecular) and marrow components of bone obtained by transiliac
bone biopsy were separated by low pressure oxygen plasma ashing and
aluminium concentration in both components, and in serum and dialy-
sate were measured by flameless atomic absorption spectroscopy.
Aluminium removal during dialysis totalled 600, 500, and 350 mg during
treatment periods of 10, 6, and 12 months, respectively. In all patients
there was a fall in whole bone aluminium concentration of approximate-
ly 60%, bone marrow aluminium concentration falling by a greater
amount than bone apatite. Aluminium staining of undecalcified histo-
logical sections showed almost complete disappearance of aluminium
from the marrow and marked loss from bone apatite. Initial bone
histology showed osteomalacia with a calcification defect. Post-treat-
ment biopsies showed predominant osteitis fibrosa with no calcification
defect. Further improvement followed Vitamin D therapy. One patient,
previously requiring monthly transfusions, has since maintained a
hemoglobin of 9.7 g/dl. These studies confirm that Desferrioxamine is
capable of removing aluminium from both bone marrow and bone
apatite and that the calcification defect present in fracturing renal
osteodystrophy can be overcome.
Hemodialysis (HD) or renal transplantation (TP) in the treatment of
endstage diabetic nephropathy (ESDN). Y. Pirson, B. Imhoof, J. M.
Vandenbroucke, J. J. Lafontaine, J. P. Squifflet, J. P. Cosyns, G. P. J.
Alexandre, and C. van Ypersele de Strihou. Université Catholique de
Louvain, Cliniques Universitaires St-Luc, Bruxelles, Belgium. To eval-
uate the respective merits of HD and TP in the treatment of ESDN, we
reviewed 25 diabetic patients (P) (mean age, 36 years) treated between
1971 and 1980 by initial TP (3 patients) or by HD in preparation to TP
(22 patients of whom 16 were transplanted). Overall patient survival is
50% at 4 years (vs. 82% in a comparable group of nondiabetic patients).
One-year patient survival is 67% for HD alone vs. 81% after TP: This
difference is mainly due to early death in HD which thus selects
transplant candidates. The main cause of death was cardiovascular
complication in HD (six of seven deaths) and infection in TP (five of
nine deaths). Eight out of 19 first grafts (18 from cadaver donor) were
lost from rejection; graft survival is 56% at 1 year. Progression of
cardiovascular, ocular, and neurologic complications is similar in HD
and TP. Recurrence of diabetic glomerulosclerosis was documented in
one graft 65 months after TP. All nine surviving patients (two in HD,
seven in TP) have an excellent rehabilitation 30 to 105 (mean, 64)
months after initiation of treatment. Our experience suggests that,
despite a higher risk of mortality and complications compared to
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nondiabetic patients, both methods may provide a good quality survival
to patients with ESDN and that one method is not clearly superior to
the other.
Is continuous ambulatory peritoneal dialysis the best dialysis choice for
insulin-dependent diabetic patients? J. Rottembourg, F. de Groc, J. L.
Poignet, and M. Legrain. Department of Nephroiogy, Hôpital La Pitié,
Paris, France. For the last 8 years, 90 insulin-dependent diabetic
patients (IDD patients) have been treated by dialysis methods in our
department. Sixty-five patients (mean age, 41.6 years) were treated
over a period of 150 patient-years by hemodialysis (HD). More recently
continuous ambulatory peritoneal dialysis (CAPD) was proposed to 25
IDD (14 males, 11 females; mean age, 54.5 years). Cumulative duration
of treatment by CAPD was 287 patient-months. At start mean creatinine
clearance was 5.7 1.3 mI/mm. Severe extrarena! complications were
present in all patients including 8 blind patients and 14 patients with
walking impairment. CAPD was performed using a routine technique:
four bags per day. Insulin was injected four times per day intraperitone-
ally (IP) in 19 patients and subcutaneously in six. The mean fasting
blood glucose level in nine patients treated for 1 year by IP insulin was
5.8 0.7 mmoles/liter and glycosylated hemoglobin was 9.8 1.1%.
Both peritoneal (5.2 ml/min) and renal residual (4.2 mI/mm) creatinine
clearances remained stable. Major serum lipid abnormalities did not
occur with the daily use of no more than one 4.5% dextrose bag.
Average blood pressure at start (210/126 mm Hg) was controlled easily
in most patients at 1 year (140/80mm Hg), but postural hypotension was
present in six patients. Stabilization or improvement of eye lesions were
observed in 12 Out of 15 patients followed for at least 6 months.
Incidence of peritonitis was one episode every 12.2 patient-months.
Cause of drop-out were six deaths and three transfers to HD. The
actuarial survival rate was 75 and 60% at 1 and 2 years. Such results
compare favorably with the survival rate of 82 and 70% observed in the
younger HD IDD group. CAPD offers for some IDD patients many
advantages: persistence of residual renal function, control of blood
pressure, and improvement of blood glucose levels.
Parathyroid hormone (PTH) in patients with diabetes mellitus and
endstage renal disease (ESRD) on chronic hemodialysis (CHD). R. C.
Pabico, A. J. Rivero, B. A. McKenna, andR. B. Freeman. Nephrology
Unit, University of Rochester Medical Center, Rochester, New York.
We have recently observed that diabetic patients with ESRD tend to
have a lower level of serum PTH than nondiabetic patients with ESRD.
This report, an extension of this observation, compares the serum PTH
measured by the C-terminal assay of diabetic patients with ESRD on
CHD with the nondiabetic ESRD patients on CHD. Predialysis serum
total calcium (Tca), ionized calcium (Ca+ +), magnesium (Mg+ +), and
inorganic phosphate (Pi) were determined in both groups. The two
groups of patients were comparable in age, duration on CHD treatment,
and predialysis chemical variables. Both groups were on 18-hr dialysis/
week using plate dialyzer, against a bath containing 3.75 mEq/liter of
Ca+ + and 2.0 mEq/liter of Mg+ +. The results are as follows:
Diabetic Nondiabetic
patients patients
Serum (N = 15) (N = 17) P
PTH, ag/mi 5.4 3.4 24.9 11.8 <0.001
T calcium, mg/di 9.5 1.5 9.8 2.1 N.S.
Ca++, mEq/liter 2.4 0.2 2.5 0.6 N.S.
Mg++, mEq/liter 2.3 0.3 2.5 0.4 N.S.
Pi,mg/d/ 4.2±1.1 4.5± 0.8 N.S.
Serum PTH is significantly lower in diabetic patients compared with
nondiabetic patients. This finding could not be attributed to the effects
of either Ca+ + or Mg+ + on PTH secretion since these cations were
virtually identical in both groups. The possible roles of catecholamines
and other determinants of PTH secretion in these patients have yet to
be defined to explain the findings above.
Immunogenetics and immunopathology of human membranous gb-
merubo nepbritis (MGN). F. C. Bert houx, B. Laurent, J. C. Le Petit, C.
Genin, P. Laurent, F. Touraine, and J. L. Touraine. Service de
Nephrologie, Hopita/ de Beilevue, Saint-Etienne, France. In most of
our MGN patients, we have studied the HLA-A, B, DR phenotype, the
clearance of anti-D (Rhesus) coated 51Cr-labeled autologous erythro-
cytes, and the blood T lymphocytes subpopulations with monoclonal
antibodies (OK T3, T4, T8). The frequency of B8 antigen is 60.7% in 28
primary MGN (five patients associated with lupus excluded) versus
14.4% in 104 local controls (X2 = 25.74; P <0.00001; PC <0.0002). The
frequency of DR3 antigen is 69.2% in 26 MGN versus 20.3% in 74 local
controls (X2 = 20.86; P < 0.00001; PC < 0.00008). The half-life of
sensitized erythrocytes is respectively 35.36 8.50 (sD) mm in nine
controls, 65.65 66.60 mm in 20 MGN, 1752 mm in two splenecto-
mized controls, and 12 mm in one patient with hypersplenism. In MGN
patients, the half-life is increased significantly in eight patients: five
patients at time of exacerbation, two lupus patients, and one progres-
sive patient. In contrast, the half-time is 40.16 10.00 in 6 MGN with
complete remission. In primary MGN and controls, the OKT3 sub-
population is 52.89 14% versus 0.80 12.40%, respectively, the
OKT4* is 29.48 9.33% versus 36.7 8.3%, the OKT8 is 18.26
6.65% versus 21.6 4.90%, and the helper/suppressor T cells ratio (T4/
T8) is 1.75 0.67 versus 1.77 0.54 in controls. Despite primary MGN
strongly associated with B8 and DR3 antigens, we could not demon-
strate a genetic and constant abnormality either of the functional
activity of splenic macrophage Fc receptor or of the distribution of
peripheral T lymphocytes subpopulations.
T-lymphocyte subsets in primary and secondary glomerulonephritides.
A. Fornasieri, R. Sinico, G. Fiorini, D, Goidaniga, G. Colasanti, F.
Vendemia, A. Gibe/li, and G. D'Amico. Division of Nephroiogy and
Service of Immunohematology, San Carlo Hospital, Milan, Italy. T-
lymphocyte subsets, using the monoclonal antibodies OKT3 (T-cells),
OKT4 (helper/inducer cells), and OKT8 (cytotoxic/suppressor cells),
were determined in 108 patients with various forms of glomerulonephri-
tis (GN) and in 25 normal healthy controls (NH) to verify abnormalities
in the peripheral T-lymphocyte populations. The patients were divided
into two groups. Group 1: primary GN (75 patients): 30 with Berger
disease (IgAGN), 20 with membranous GN (MGN), 15 with focal
glomerulosclerosis (FGS), and ten with membranoproliferative GN
(MPGN). No patient of this group received corticosteroids or immuno-
suppressive drugs at the time of the study. Group 2: secondary GN: 18
patients with systemic lupus erythematosus and 15 with essential mixed
cryoglobulinemia. We found a significant increase P < 0.001) in OKT4/
OKT8 cells ratio in patients with MGN and IgAGN vs. NH; this was
due to a significant decrease in OKT8 cell percentage. On the other
hand, no abnormality was found in patients of group 2 and especially in
lupus GN (the patients of this group were receiving corticosteroids or
immunosuppressive drugs at the time of the study). Altlqpgh these data
must be interpreted with great caution and further studies are neces-
sary, our results suggest an imbalance in immune regulatory mecha-
nisms in some forms of GN (MGN and IgAGN).
Abnormalities of immune regulation in patients with IgA nephropathy.
J. Egido, R. Biasco, J. Sancho, and L. Hernando. Fundación Jiménez
DIaz, Madrid, Spain. The aim of this work was to determine the cellular
abnormalities that could explain the high levels of serum IgA frequently
observed in patients with IgA nephropathy. Peripheral blood lympho-
cytes (PBL) from patients with IgA nephropathy (N = 22) culture4 in
vitro for 7 days produced, after Pokeweed mitogen (PWM) stimulation,
significantly higher amounts of IgA than the control group (N = 15). No
differences were observed in the synthesis of IgG and 1gM. Most
patients presented an increase in helper T cells (OKT 4+) in relation to
the control group, with normal percentages in suppressor/cytotoxic T
cells (OKT 8+). Sixty percent of patients showed an impairment in IgA-
specific suppressor T cell activity generated by Concanavalin A. In co-
culture experiments an increase in the T helper function specific for IgA
was found. Some of these alterations were also observed in some
healthy patients' relatives of five families studied. Our results show that
patients with IgA nephropathy present a specific increased production
of IgA in vitro probably due to an abnormality in T helper function with
a secondary loss of IgA-T suppressor activity. These immunoregulatory
abnormalities could be the first step in the pathogenesis of the disease.
1gM and IgA2 in circulating immune complexes and in renal deposits
of Berger and Henoch-Schönlein gbomerulonephritis. R. Coppo, B.
Basolo, G. Mazzucco, M. Messina, G. Barbiano, and G. Piccoli.
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Nephrology Units, S. Giovanni Hospital, Turin and Cd Granda Hospi-
tal, Milan, and Pathology Institute of the University of Turin, Italy. The
first parallel analysis of IgA subclasses in sera and mesangial deposits of
patients affected by Berger's (BGN) and Henoch-SchOnlein (HSGN)
glomerulonephritis were presented, while conflicting data have been
reported by others on kidney tissue. This study was carried out on 29
BGN and 12 HSGN by investigating: (1) IgA immune complexes
(IgAIC), IgA1IC, IgA2IC (original conglutinin assay), (2) serum IgA,
IgAl, IgA2 (immuno-enzymatic assay), (3) polymeric IgA (reduction-
alkilation test), (4) IgAl and IgA2 in renal deposits (indirect IF). Both
IgAl and IgA2 were about equally represented in renal deposits. In sera
IgAIC were significantly higher than controls (128 316 vs. 6.5
aggr. IgA/mI, P < 0.01). The serum IgA2IC/IgA1IC ratio was found to
be significantly increased in comparison to serum IgA2/lgAl, being
similar to that observed in mucosal plasma cells. An increase of
polymeric IgA was observed in 28.8% of the sera. These data suggest
that IgA in IgAIC and in renal deposits are of mucosal origin, in
agreement with experimental models.
Presence of J chain in mesangial immunodeposits of IgA nephropathy
(IgANP). U. Donini, C. Casanova, G. Maletta, and P. Zucchelli.
Divisione di Nefrologia e Dialisi and Laboratorio di Microscopia
Elettronica of Ospedale M. Malpighi, Bologna, Italy. Recent studies
indicate the possible involvement of polymeric IgA in pathogenesis of
IgANP. Using indirect and direct immunofluorescence and immunoper-
oxidase (PAP), we investigated the presence of J chain in mesangial
immunodeposits of 22 patients with IgANP, one patient with alcoholic
liver cirrhosis (ALC) and nine other patients with different nephropa-
thies (NP) used as controls. Before immunostaining the cryostat
sections were incubated in glycine buffer containing 6 xi urea. We used
goat and rabbit anti-J antisera, which had been absorbed previously
with human immunoglobulins and guinea pig liver powder to exclude
nonspecific reactions. Our results indicate that J chain is present in 18
out of 22 patients of IgANP (81.1%), in a patient with ALC and one with
focal glomerulosclerosis with lumpy deposits of 1gM. However it is
absent in the remaining NP which were used as controls. The four
patients with IgANP lacking immunostaining for J chain, presented
lumpy and abundant mesangial IgA deposits. The presence of J chain
seems to correlate not to the quantity of IgA deposits but to their
quality. Thus we can recognize two populations of IgANP: one with
polymeric IgA and the other without polymeric IgA in mesangial
deposits.
Clinical features of mesangial IgA glomerulonephritis (IgA-GN). M.
Rarnbausek, W. Seelig, K. Andrassy, R. Waldherr, V. Lenhard and E.
Ritz. Departments of Internal Medicine, Pathology and Serology,
University of Heidelberg and Institute for Immunology, Karlsruhe,
Heidelberg, Federal Republic of Germany. Several clinical features of
IgA-GN are currently controversial. The present study analyzed clini-
cal, immunological, and anatomical data of 50 patients with IgA-GN
confirmed by renal biopsy. IgA-GN was found in 20% of all GN-
patients with renal biopsy. Twelve of 40 patients (30%) with IgA-GN
had IgA-deposits in clinically noninvolved skin, but also five of 23
(22%) patients with non-IgA-GN, but none of 50 volunteers. Six of 50
patients had renal failure (serum creatinine >1.4 mg/dl) at the time of
biopsy and an additional 11 developed renal failure during the 4 to 96
months follow-up. Three patients went on hemodialysis. Elevated IgA
(>312 mg/dl) were present in 22 of 43 patients and circulating IgA
complexes (Raji-assay, RSL-assay, C1Q-PEG-assay) in 8 of 33 patients.
There was no increased incidence of HLA-B12, BW3, or BRW4 and the
clinical course in HLA-B35 positive patients was not worse. Hyperten-
sion was present in 12 of 22 patients, five of whom had malignant
hypertension. Poor prognostic indicators were male sex, hypertension,
age >30 years, and histological findings of glomerular sclerosis, tubular
atrophy, interstitial fibrosis, and vascular lesions. IgA immune deposits
were IgA2 in 70%, IgA1 in 15% and both IgA1 and lgA2 in 15%.
Controlled trial of monthly alternated courses of steroid and chioram-
bucil in idiopathic membranous nephropathy (IMN). C. Ponticelli, P.
Zucchelli, F. Locatelli, C. Grassi, D. Limido, T. Volpini, and E.
Imbasciati. Renal Units of Policlinico-Milano, Malpighi-Bologna
Lecco, Melegnano, Monza, Magenta Hospitals, Milan, Italy. A new
therapeutic regimen was evaluated in IMN by a prospective controlled
multicenter trial. Treatment schedule: three intravenous methyiprednis-
olone pulses 1 g for 3 days followed by oral prednisone 0.5 mg/kg/day
for I month and then by chlorambucil 0.2 mg/kg/day for the subsequent
month. Three consecutive courses of this regimen were administered
for a cumulative period of 6 months. Patients were randomly allocated
to a treatment (T) or to a control (C) group. Three T patients dropped
out because of gastric ulcer, diabetes, or gastric intolerance to chlora-
bucil. No other major side effects were observed. We evaluated the
outcome of 21 T and 23 C patients followed for 1 to 5 years.
End follow-up Mean
— follow-upCR PR U W (months)
6 months
Results CR PR U W
T 7 7 7 — 9 6 6 — 24.5
C — 2 18 3 2 6 12 3 29.8
Abbreviations: CR, complete remission; PR, partial remission (protein-
uria g/24 hr); U, unchanged; W, worsened (serum creatinine
increase of basal value).
Our data show that this treatment may obtain a high rate of complete
and sustained remission of proteinuria and prevent, at least at short-
term, renal function determination in IMN.
Aggressive treatment with pulse methylprednisolone (PMP) or plasma
exchange (Px) is justified in rapidly progressive crescentic glomerulone-
phritis (RPGN). M. E. Stevens, M. McConnell, and J. M. Bone.
Regional Renal Unit, Royal Liverpool Hospital, Liverpool, United
Kingdom. RPGN carries a poor prognosis. In recent years several
studies reported successful treatment using PMP and/or Px. There is
evidence that a better outcome follows early aggressive treatment
before the onset of severe renal impairment. We have treated 28
patients with biopsy proven RPGN from 1978 to 1982 in this center.
Nineteen patients received PMP (I g methylprednisolone iv. daily for
3 to 5 days); 13 patients were treated with Px (2 to 3 liters/day for 4 to 10
days). The outcome in these patients was significantly better than the
outcome in a group of 20 patients who presented between 1974 and 1978
who did not recieve PMP or Px. In both groups, patients received oral
prednisolone and other immunosuppressive agents. There was no
difference between PMP and Px in terms of rapidity and extent of
response or long-term survival off dialysis. Of 17 patients who respond-
ed to PMP or Px, nine presented with advanced renal failure and
oligoanuria needing dialysis, and six have stable renal function off
dialysis, after 3 years. Extra-renal involvement, older age, longer
history, greater residual renal function and negative immunofluores-
cence were good prognostic factors. No serious side effects of either
form of treatment was seen. Both PMP and Px are effective and safe
methods of treatment in a condition which otherwise leads to death or
dialysis.
Plasma exchange in severe glomerulonephritis: Who benefits? C. P.
Swainson and J. S. Robson. University Department of Medicine,
Edinburgh, United Kingdom. Plasma exchange (PE) and immunosup-
pression was used in the treatment of 17 patients with acute glomerulo-
nephritis and renal failure and in eight cadaver renal transplant recipi-
ents undergoing acute rejection. Sequential renal biopsies, serum Clq
binding, complement, immunoglobulins, anti-GBM antibody, renal
function and urinary protein excretion were performed in all patients.
The response to treatment divided patients into three groups: (1)
Idiopathic crescentic nephritis/Goodpasture 's disease. No patient made
a satisfactory long-term response although most showed some tempo-
rary improvement. Oliguria-anuria indicated a poor prognosis. (2) A
temporary response was seen in a heterogeneous group of patients who
all relapsed 3 months after PE despite continuing immunosuppression.
(3) Good responders. A second heterogeneous group of patients who
have stable renal function after at least 3 months follow-up. Responders
could not be predicted on histology alone but plasma creatinine fell
more than 40% during the first 10 days of PE. Increased proteinuria was
also an early sign of response. Plasma exchange may be useful in severe
glomerulonephritis complicated by crescents in renal failure but did not
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alter the prognosis in severe crescentic nephritis which healed by
fibrosis. A short course of plasma exchange produces the desired effect.
Participation of renal prostaglandins in the nephrotic syndrome. V.
Gutierrez Millet, L. M. Ruilope, J. M. Alcazar, C. Prieto, J. F.
Tresguerres, R. Garcia Rob/es, and J. L. Rodicio. C.S.S.S. "1-s de
Octubre." Madrid, Spain. To investigate the participation of renal
prostaglandins in the maintenance of renal function in nephrotic syn-
drome, the urinary PGE2 excretion has been measured together with
body weight (BW), blood pressure (BP), glomerular filtration rate
(GFR), proteinuria (P), natriuresis (UNa), PRA and plasma aldosterone
(A), before and after Indomethacin (1) administration (2 mg/kg body
weight/day x 3 days) in a group of 21 patients with the diagnosis of
normotensive chronic idiopathic glomerulonephritis. Twelve patients
had nephrotic syndrome (NS) (proteinuria >3 g/day) and 27 normoten-
sive volunteers sex- and age-matched were the control group (CG). The
patients with NS showed lower values of UNa (P < 0.05) and higher
values of PRA (P < 0.02), A (P < 0.05) and uPGE2 (P <0.01) than those
without NS and CG. The administration of I induced in NS patients an
increase in body weight (P < 0.02) along with a decrease in GFR (P <
0.01), P (P < 0.01), UNa (P < 0.05), PRA (P < 0.01), A (P < 0.01) and
uPGE2 (P < 0.01). BP did not change. In patients with glomerulonephri-
tis without NS, I induced a decrease in P (P < 0.01), PRA (P < 0.01), A
(P < 0.01), and uPGE2 (P < 0.01) and no changes in BW, BP, GFR, and
UNa. Two days after I discontinuation the alterated values returned to
the previous levels. In NS patients the I induced proteinuria decrement
(—P), correlated with the —PRA (r:0.711, P < 0.02) and —uPGE2
(r:0.759, P < 0.02) but not with —GFR. The —EGFR correlated only
with basal uPGE2 levels (r:0.636, P < 0.05). Conclusions: The mainte-
nance of GFR in NS is achieved by increase in renal PGE2 production.
The antiproteinuric effect of I seems to be dependent on the inhibition
of renin and renal PGE2 synthesis.
Why diuretic treatment increases azotemia in patients with chronic
glomerulonephritis (CGN)? A. Dat Canton, C. Fuiano, G. Conte, M.
Terribile, M. Sabbatini, B. Cianciaruso, and V. E. Andreucci. Chair of
Nephrology, Second Faculty of Medicine, University of Naples, Napo-
Ii, Italy. The mechanism of diuretic-induced hyperazotemia was studied
in three groups of patients with CGN and renal failure (GFR = 10 to 50
ml/min), that were treated with furosemide (F), 50 to 250 mg/day, for 7
days. Group 1: in six patients, clearance of creatinine (Cor) and of urea
(Cur), filtered urea (Ureaf), urinary urea excretion (Urea), and body
urea nitrogen appearance (UNA) were measured daily before and
during F. Group 2: Six patients were studied as in group 1, but body
weight was maintained constant by administering a daily amount of
Na equal to the excreted one. Group 3: In eight patients, Cur, Ccr, and
osmolar clearance (Cosm) were measured before F, on the last day of F,
and 3 days after its interruption, during maximal water diuresis, to
calculate proximal tubular reabsorption (Rprox). In group 1, F raised
azotemia by 54%; Cur fell by 35%, while Ccr was unchanged. Urea, was
low in the first days of treatment, but then returned toward normal due
to the rise in Ureaf. UNA rose by 27%. In group 2, none of the aforesaid
changes was observed. In group 3, C, fell similarly in the last day of F
(when Rpro. was reduced by 7%) as after interruption of F (when Rprox
was increased by 5%). These results show that the rise in azotemia is
not due to a fall in GFR (as commonly believed) but to increased distal
tubular reabsorption of urea and to increased UNA. Both these effects
are dependent on body fluid volume depletion.
Renovascular hypertension (RVH): Easier diagnosis and treatment
with intravenous renal arteriography (IRA) and percutaneous translu-
minal angioplasty (PTA). D. Delambre, J. P. Cécile, A. Rémond, P.
Fiévet, Y. Grumbach, and A. Fournier. CHR Lens, CHU Amiens,
France. IRA was performed by rapid injection of an i.v. bolus (2 to 3 ml/
kg) of a 38% contrast medium with an automatic injector and a film
changer which is turned on when the bolus reaches the 11th dorsal
vertebra, to present six films at 2-sec interval. The film preceding
abdominal aorta opacification is used for substraction. Then films are
taken for pyelography at 5 and 15 mm as well as 2 to 4-6 mm after
intravenous injection of 40mg of furosemide when a stenosis is present
to assess its significance. Hypertensive patients (848) had this proce-
dure without complications. Diagnostic accuracy was 95%. Renal
artery stenosis was discovered in 62 (7.3%). Cost-effectiveness calcula-
tion shows that IRA for RVH diagnosis is 25% cheaper than the
classical approach based on Seldinger arteriography after previous
selection on clinical and urographic criteria. PTA was performed in 26
of these patients because their surgical risk was high and their stenosis
(4 fibrous dysplasia, 22 atherosclerosis) was found significant on
furosemide pyelogram wash out and/or a renal vein renin ratio 1.5.
Dilatation was not possible in four patients and minor complications
occurred in four patients. A lethal hemiplegia occurred rapidly after
normalization of hypertension in a man with carotid stenosis. Six
months after the first PTA, five hypertension patients were cured, 11
improved and 5 remained unimproved. A second IRA was then
performed in 10 and showed restenosis in five. Five patients had a
second PTA and one a third. After 13 to 26 months, hypertension was
cured in six, improved in nine and unimproved in six patients. Conclu-
sions: (1) IRA preceding pyelography with furosemide wash out is the
method of choice for the diagnosis of RVH. (2) PTA is a valuable
alternative to surgery for the treatment of RVH despite a relatively high
incidence of restenosis in atherosclerotic patients. This warrants a
controlled trial versus surgery with an unselected RVH population.
Beta adrenergic modulation of extrarenal potassium disposal in termi-
nal uremia. A. Martinez-Vea, J. Montoliu, L. Andreu, A. Torras, J.
López-Pedret, and L. Revert. Hospital Clinic, Barcelona, Spain. To
study the effect of epinephrine (E) on potassium (K) metabolism, an E
infusion (0.1 sg/kg mm for 30 mm) was carried out in 12 essentially
anuric and usually hyperkalemic maintenance hemodialysis (HD) pa-
tients, 72 hr after their last HD. Immediately following the E infusion
two groups emerged. In group I (six patients), serum K decreased from
a basal value of 6.5 0.5 (mean Sn) to 5.4 0.2 mEq/liter and there
were increases in heart rate (68.6 6 to 85.3 8 bpm), serum glucose
(76 5.7 to 122.6 15.5 mg/dl) and insulin levels (15.1 4.8 to 22.3
3.9 mU/ml). In group 2 (six patients), serum K did not decrease (6.1
0.8 to 6 0.9 mEq/liter), and heart rate remained unchanged (70.6 7
to 79.6 15 bpm, P = NS), but serum glucose and insulin did increase
(84.8 8.5 to 120.3 14.4 mg/dl and 16.5 1.3 to 21 3.7 mU/mi,
respectively). Plasma renin, aldosterone, and arterial pH did not change
in either group. Propranolol (1.4 pg/kg. mm for 30 mm), when adminis-
tered simultaneously with E to four patients from group I, totally
blocked the decrease in serum K (6.6 0.5 to 6.6 0.4 mEq/liter).
Patients from group 2 had higher preinfusion endogenous E levels than
patients from group 1(316.6 213.2 vs. 139.2 78.3 pg/mI, respective-
ly). Thus, in HD patients, beta adrenergic stimulation enhances extrare-
nal K disposal, but 50% of patients may fail to lower K with E infusions,
perhaps because of receptor occupancy due to higher endogenous E
levels.
Hereditary glomerulonephritis of non.Alport type in three families. C.
C. Doherty, D. T. C. Middleton, and C. M. B. Hill. Renal Unit, Belfast
City Hospital, and Department of Pathology, Queen's University of
Belfast, Belfast, Northern Ireland. Forty-three members of three
families with hereditary renal disease were studied and 21 affected
individuals were identified. The predominant clinical features were
asymptomatic hematuria and/or proteinuria, and there was a preponder-
ance of females (16) vs. males (5). Three of the 16 females but none of
the 5 males developed progressive renal failure and required dialysis
and transplantation. No patient manifested deafness or any of the
stigmata associated with Alport syndrome and none had hypocomple-
mentemia or amino aciduria. The hereditary pattern was consistent with
an autosomal dominant mode of inheritance in the three families. Renal
biopsy carried out in six of the 21 patients showed varying degrees of
mesangial change and on immunofluorescence the main finding was
glomerular C3 deposition associated with 1gM in some of the cases.
Foam cells were only present in two patients (both from the same
family) and typical ultra-structural changes of Alport syndrome were
absent. Three families are therefore described with hereditary renal
disease in which females are predominantly affected with a variable
outcome. The mode of inheritance is autosomal dominant and the
morphological lesion is a form of mesangial proliferative glomerulone-
phritis. This description does not conform with previously recognized
types of familial nephropathy.
Survival time in cystinosis. A collaborative study. N. Gretz, F. Manz,
T. M. Barratt, M. Brandis, H. J. Bremer, J. Brodehl, M. Broyer, M.
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Bulla, L. Callis, C. Chantler, L. Diekmann, M. J. Dillon, F. Egli, J. H.
H. Ehrich, W. Endres, A. Fanconi, C. Feldhoff, J. Geisert, D. Gekie, B.
GeschOll-Bauer, K. Grote, R. Grdttner, W. Hagge, G. B. Haycock, H.
Hennemann, B. Kiare, D. Leupold, H. LOhr, D. Michalk, F. Ott, K.
Pistor, J. Rau, K. Schärer, F. Schindera, H. Schmidt, H. Schulte-
Wissermann, K. Verrier-Jones, H, P. Weber, U. Willenbockel, and H.
Wolf. Clinic of Nephrology, University of Heidelberg, Mannhejm,
Federal Republic of Germany. In a retrospective study of 188 patients
having infantile or adolescent cystinosis the following data were used
for a survival analysis applying the method of product limit: date of
birth, date of death occurring before the onset of terminal renal failure
(22 patients), date of death due to uremia, starting date of renal
replacement therapy, date of last observation. The median survival time
was determined to be 8.8 years (25th percentile, 7.5 years, 75th
percentile, 10.8 years). The survival curve exhibits at least two compo-
nents: a linear fall due to nonrenal deaths before the onset of terminal
renal failure and an exponential fall caused by renal deaths. No plateau
formation was noted at the righthand end of the survival curve
indicating no clear cut difference between infantile and adolescent
cystinosis. Prognostic factors influencing survival time were assessed
using the Cox proportional hazards linear model. The origin of the
patients and sex had no prognostic significance. Age was seen to be
significant when the serum creatinine level was approximately 2 mg%.
The data obtained can be used to evaluate the influence of new
therapeutic measures on the survival of children with cystinosis.
Fc-receptor function in Henoch-Schönlein disease of childhood. J. C.
Davin, J. B. Foidart, and P. Mahieu (Introduced by J. P. Gordon).
Stare University of Liege, Liege, Belgium. The Fc-receptor function of
circulating monocytes (CM) and of splenic macrophages (SM) has been
measured sequentially in seven children presenting with a Henoch-
SchOnlein disease without urinary abnormalities (two patients), with
transitory hematuria (two patients), hematuria and albuminuria (two
patients), and hematuria and nephrotic syndrome (one patient). The Fe-
receptor function of CM was classically determined in vitro using IgG-
coated erythrocytes, whereas the Fc-receptor function of SM was
determined in vivo, 40 mm after the intravenous injection of 99Tc-heat-
damaged autologous erythrocytes, using a gamma camera. Results
showed: (1) the Fc-receptor function of CM was strongly decreased
during the acute phase; (2) when a clinical improvement occurred, a
reversal of this Fc-receptor blockade was noted; (3) a reversal of this
Fc-receptor blockade was also observed after trypsin treatment of CM;
(4) the Fc-receptor function of SM was also abnormal in the five
patients with nephropathy; (5) the Fe-receptor blockade was not
significantly correlated with plasma levels of C3, C4, C3PA, and
immune complexes measured by the C10 binding assay or by the
conglutinin assay; (6) the C3-receptor function of CM remained normal
during the course of the disease. The data show that a decrease of Fc-
receptor function of CM often associated with an impairment of splenic
function is observed in Henoch-SchOnlein disease of childhood and that
functional defects are transient when the disease presents a favorable
outcome.
Altered hemostasis in children with nephrotic syndrome (NS)—Is there
a difference to adults with NS? P. J. Oertel, K. Andrassy, 0. Mehls, E.
Ritz, and T. Lipkow. Departments of Pediatrics and Internal Medicine,
University of Heidelberg, Federal Republic of Germany. A high risk of
venous thromboembolic complications exists in patients with NS,
primarily due to a disturbance of the plasmatic coagulation system. In
contrast to adults we observed arterial thromboses in several children.
This points to an important role of platelets in genesis of thrombosis in
children. To test this hypothesis, the following coagulation studies were
performed in nine children (5 to 13 years) and 32 adults with NS and no
recent thromboembolism: platelet counts, platelet-induced aggregation
with ADP, collagen and epinephrine, circulating platelet proteins (/3-
thromboglobulin(/3-TG), platelet factor 4 (PF-4), prothrombin time,
partial thromboplastin time, fibrinogen, antithrombin III (AT III) and
soluble fibrin monomer complexes (SFMC). Renal function, serum
albumin (A), and urinary proteins were evaluated with standard meth-
ods. Results: A was significantly lower in children (2.0 0.8g/dl) than
in adults (2.75 1.0 gldl) with NS. AT III was uniformly decreased in
children (protein 56.5 27%; activity 65 31%), but not in adults (100
15%; 103 18%). AT III and A were inversely correlated. SFMC
were significantly elevated in children (7.8 3.4%), not in adults (4.9
0.4%). /3-TG and PF-4 were high in four of eight children vs. one of 18
adults with normal GFR. A significant increase of collagen-induced
aggregation was found in both groups. Conclusions: In contrast to
adults in children with NS an excessive activation of platelets and the
plasmatic coagulation system was found. As an index of low grade DIC
AT III was significantly reduced and SFMC were increased in children.
This may explain the increased risk of arterial thrombosis in children
with NS.
HLA phenotypes and clinical course of idiopathic nephrotic syndrome
in children. H. Ruder, K. Schärer, V. Lenhard, A. M. Wingen, and G.
Opelz. Institute of Immunology and Children's Hospital University o.f
Heidelberg, Federal Republic of Germany. Associations between HLA
antigens and idiopathic nephrotic syndrome (INS) have been described
by several authors. We studied the influence of HLA antigens on the
clinical course of INS. Children (131) were analyzed; 40 had steroid
resistant focal segmental glomerulosclerosis (FSGS) and 91 were ste-
roid responsive. Fifty-five of them showed minimal change lesions
(MC) proven by biopsy. All patients were typed for HLA-ABC, 78 also
for HLA-DR. Antigen frequencies were compared to 100 healthy
controls. INS patients showed a significant increase of DR7 (56% vs.
18%, P < 0.001, relative risk 5.7) and B8-DR3 (27% vs. 5%, P < 0.05,
relative risk 6.4). Neither B8 positive, DR3 negative nor B8 negative,
DR3 positive patients showed an increased relative risk for INS. The
simultaneous presence of B8, DR3, and DR7 was found in 14% of
patients but in none of the controls. Interestingly, this combination was
more often found in MC patients with frequent relapses and in FSGS
patients than in MC patients with infrequent relapses. Our data indicate
that both major histocompatibility complex-carrying chromosomes may
be involved in the pathogenesis of INS. INS predisposing genes seem to
occur with either HLA DR7 or HLA B8-DR3. The simultaneous
presence of both HLA markers coincides with a severe course of
disease.
Continuous ambulatory peritoneal dialysis in children with acute renal
failure. F. C. B. Abbad and S. L. B. Ploos van Amstel. (Introduced by
E. T. Krediet). Department of Pediatrics, Academic Medical Center,
Amsterdam, the Netherlands. To overcome the problems of the cata-
bolic situation in the anuric stage in small children with acute renal
failure continuous ambulatory peritoneal dialysis was preferred. This
form of dialysis was performed in five children (weight < 15 kg) with
acute renal failure due to hemolytic uremic syndrome. Their ages
ranged from 3 weeks to 2 years 8 months (average age, 1 year 4
months), body weight 2.8 to 14.8 kg (average 10 kg). Acute peritoneal
dialysis was performed with a stiff catheter, inserted through puncture
under local anesthesia during the first 48 hr. Thereafter a Thenckhoff
catheter was implanted under general anesthesia. Continuous ambula-
tory peritoneal dialysis was continued until the creatinine clearance
reached 20 ml/min/l .73 m2. Duration of this treatment ranged from 10 to
33 days (average, 21.5 days). A normal diet was possible (protein intake
up to 3 g/kg/day) with only a small fluid intake restriction. During
treatment immobilization was not necessary and normal activities were
encouraged. A real gain of weight was seen in the youngest patient
(2800 to 3150 g) while the other four patients retained the same body
weight.
Improved kidney graft survival through HLA-DR-MT-matching. G.
Muller, C. Muller, and P. Wernet (Introduced by H. Schneider)
Department of Medicine III, University Tilbingen, Immunology Labo-
ratory, Department of Medicine II, University Tubingen. MHC coded
antigens are responsible for the strongest rejection reactions in kidney
transplantation. Retrospective analysis demonstrated that matching for
HLA-DR antigens seems to be of more relevance than matching for
HLA-AB. During the last 2 years 85 patients on the waiting list were
transplanted within the South German Cooperative Study Group for
Kidney Transplantation. Selection policy was done for the best HLA-
DR match as first priority and for the best HLA-AB match as second
priority. HLA-DR typing was performed on B-cells enriched by nylon
wool filtration using 50 locally well characterized HLA-DR antisera and
the antisera of the 8th International Histocompatibility Workshop
(disease set) which allowed the definition of newly defined MT-
specificities. MT is a newly defined alloantigen system in high linkage to
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HLA-DR. All Ii HLA-DR identical grafts were functioning at 1 year
and reached a 2-year graft survival rate of 82% which was better than
for grafts mismatched for 1 HLA-DR antigen (60%, 2 years). Grafts
mismatched for 2 HLA-DR antigens reached a 2-year graft survival rate
of only 47%. Retrospective analysis showed that grafts identical for 2
MT-specificities (N = 17) reached a 2-year graft survival rate of 95%
which was even better than for HLA-DR identical grafts. Patients
mismatched for 2 MT-specificities (N = 12) reached a 2-year rate of a
mere 17%. Grafts mismatched for 1 HLA-DR antigen but identical for 2
MT-specificities were in 94% functioning after a period of 2 years.
These results suggest that the MT-system even more so than the HLA-
DR alleles could be of critical importance for graft survival in cadaver
kidney transplantation.
Acute renal allograft rupture—A good prognostic sign? J. A. C.
Buckels, M. Y. Ezzibdeh, and A. D. Barnes. Renal Unit, Queen
Elizabeth Hospital, Birmingham, England. Of 320 patients undergoing
cadaveric renal transplantation at one center between May 1978 and
January 1982, 10 (3.1%) developed acute cortical rupture between the
second and ninth postoperative day. All developed severe pain in the
region of the graft and showed signs of graft enlargement and tender-
ness with evidence of hypovolemia. Urgent graft exploration was
carried out which revealed perigraft hematoma arising from cortical
ruptures. The grafts were edematous but none had macroscopic fea-
tures of rejection, evidence of vascular or ureteric obstruction. Surgical
management was evacuation of hematoma and control of bleeding. No
graft required removal at the time of initial exploration. Biopsy at
exploration in nine patients showed either no rejection (4) or mild
rejection only (5). Seven patients had satisfactory graft function at an
average follow-up of 17.1 months. Three grafts were lost, one rejection
after 35 days and two renal vein thrombosis at 12 and 14 days. No
etiological factor was evident (rejection, ureteric, obstruction, drug
therapy, dialysis, or graft biopsy) although total ischemic times tended
to be long (average, 17 hr). This experience shows acute renal allograft
rupture is a relatively benign complication of renal transplantation and
leads to a satisfactory outcome in the majority of patients.
Suppressor factor in plasma of aminophylline treated renal transplant.
ed patients. Z. Shapiro, B. Shohat, and C. Servdio. Transplant Unit,
Urological Department and Clinical Immunology Laboratory, Beilin-
son Medical Center, Petah Tiqva, Israel. The present study was
undertaken to find out whether aminophylline can be used in renal
allograft recipients for activation of the T-suppressor cell subset.
Twenty-six patients who underwent allogenic cadaver transplantation
are involved, in all of them evidence of acute rejection episodes was
observed during the study and 15 of them were given aminophylline
1000 mg daily orally after cessation of high-dose steroid therapy.
Monitoring of lymphocyte subpopulations in the above 26 patients were
performed. The suppressor activity of the isolated cells was assessed by
the local xenogenic graft-versus-host-reaction (GVIJR). Furthermore
the plasma obtained from the patients treated by aminophylline as well
as from the untreated patients was tested for suppressor activity in the
same model of the local xenogenic GVIIR. Reversal of the acute
rejection episode was observed in 11 of the 15 aminophylline treated
patients and was correlated with increasing amounts of T suppressor
cells in their peripheral blood. In nine of these patients the suppressor
factor was demonstrated as their plasma inhibited the ability of normal
human lymphocytes to induce a local GVIIR. No such activity was
found in most of the untreated patients.
Outcome of renal grafts with multiple or damaged vessels. A. Vegeto,
L. Berardinelli, C. Beretta, and L. Militano. Department of Vascular
Surgery and Kidney Transplantation, Osp. Policlinico of University
Milano, Milano, Italy. This paper describes our efforts to increase the
number of cadaver grafts available, using kidneys with multiple renal
arteries or grafts whose normal vascular anatomy has been damaged
during donor nephrectomy for transplantation. in our series of 551
kidney transplantations 134 times an alternative method of arterial
anastomosis and 27 ligations of thin parenchimal arteries were em-
ployed. A change of the surgical technique was required only 24 times
for the presence of multiple renal veins, while 54 multiple renal veins
were tied. No significative difference was noted in the postoperative
course concerned with the incidence of hypertension, the number of
graft nephrectomies for irreversible rejection crisis, the appearance of
urinary fistulas and polar infarct. On the other side, the incidence of
postoperative tubular necrosis was a little higher in kidneys with
multiple arteries. The late graft survival time of the two groups are
similar with the actuarial methods in our experience.
Intravenous methyl prednisolone at the time of renal transplantation.
A. Heaton, R. Wilkinson, W. Elliott, and R. M. R. Taylor. Freeman
Hospital, Newcastle upon Tyne, United Kingdom. Since February 1978
it has been the policy in Newcastle to give intravenous methyl predniso-
lone 1000mg at the time of renal transplantation and a further dose 24 hr
later. To study the effects of this, we compared 95 patients transplanted
before this policy change (group A) with 112 patients after the change
(group B). Eight-one (59.6%) patients in group B received a B locus
matched kidney, compared to 46 (48%) patients in group A. There was
no difference in transfusion history between the two groups. Twenty-
four (17.5%) in group B, compared to 10 (10.5%) in group A, received
kidneys from a living relative. We found no difference in the incidence
of diagnosis of acute rejection in the two groups within the first 40 days
after transplantation. One hundred and twelve episodes were diagnosed
in A (1.18 episodes/patient) and 153 episodes in B (1.13 episodes/
patient). Peak incidence occurred 5 days post-transplantation in both
groups. Diagnosis of rejection within 48 hr of transplantation was,
however, reduced in group B, with two episodes diagnosed, compared
to 12 in group A. Patients in A received a mean of 4.45 g of methyl
prednisolone within the first 40 days, compared to 5.70 g in B. Five
patients in A and 15 in B received 10 g or more of methyl prednisolone.
Intravenous methyl prednisolone at the time of transplantation does not
reduce the incidence of acute rejection and exposes more patients to the
risks of high dose steroid therapy.
Improvement of cadaveric renal allograft.survival by thoracic duct
drainage: Relations with T-lymphocyte subset modifications assessed by
flow-cytometry. M. Laville, G. Cordier, J. Brochier, R. Lefebvre, J. P.
Revillard, and J. Traeger. Clinique de Nephrologie, Hôpital F. Herriot,
Lyon, France. Thoracic duct drainage (TDD) has been shown to
improve allograft survival in humans, but the immunoregulatory mecha-
nisms of this beneficial effect remain poorly understood. TDD with
reinfusion of cell-free lymph was performed in 78 prospective recipients
within 3 months before transplantation. TDD was unsuccessful in 24
patients (A); it yielded Ito 20 x l0 lymphocytes in 14 patients (B) and
20 to 185 x l0 in 40 patients (C). The incidence of acute rejection
episodes and the requirement for early post-transplant dialysis were
lower in C than in A. Five patients were studied for T-lymphocyte
subsets, using monoclonal antibodies from the OKT series and a
monomorphic anti-HLA-DR (BL2) raised in our laboratory. During
TDD, peripheral blood lymphocyte (PBL) counts decreased, and the
percentage of BL2* cells increased. Simultaneously, typical small PBL
were replaced by large, less differentiated cells slightly labeled by
OKT3, some of them bearing both OKT4 and OKT8 markers. The
larger the depletion, the earlier the emergence of immature T-cells. In
lymph fluid, lymphocyte counts decreased later than in blood; the
proportion of T8 cells lacking receptors raised with time. Changes
in B patients were weaker than in C. These results support the
hypothesis that T-cell subset modifications represent the main immuno-
logical change accounting for a better allograft prognosis.
Comparison of urine cytology (UC) versus fine needle aspiration
cytology (FNAC) in monitoring renal allograft dysfunction. B. Spohn, R.
Guth, H. Bauer, F. Gmdhle, and H. F. Franz. Sektion Nephrologie der
Universitdt Ulm, Donau, West Germany. In patients with renal allo-
graft dysfunction we performed daily UC-preparations (N = 659) and
FNAC specimens (N = 147) 2 to 3 times per week in 29 allograft
recipients. Clinical rejection criteria included fever, reduction of uri-
nary output, graft tenderness, hypertension, and an increase of> 0.3
mg% in serum-creatinine. The UC-pattern of acute rejection (AR)
shows on consecutive days per 10 high power fields (HPF's) more than
20 small collecting duct cells and/or more than 10% lymphocytes!
inflammatory cells, respectively more than 20 lymphocytes/b HPF's,
often accompanied by increased cellular and amorphous background
and pathologic casts. The FNAC diagnosis of AR is based on an
increase of lymphoblasts, plasmablasts, plasmacells, lymphocytes,
monocytes, and macrophages in the biopsy specimen compared with
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the same cells in the peripheral blood. In 14 of 16 the diagnosis of AR
was established by UC 4 to 1 days before or on the day of the event, in
two patients shortly after AR. In the FNAC preparations the diagnosis
of AR could be confirmed in 13 of 16 patients. Three times the FNAC
was false negative. Seventeen of 147 FNAC specimens gave false
positive results; 11 of 147 specimens contained no graft material. One
patient showed a postpuncture intrarenal hematorna and macrohema-
tuna. Nonrejection causes of graft dysfunction like tubular injury due to
nephrotoxic drugs, interstitial nephritis (allergic type, pyelonephritis,
viral and fungal infections) disclose a clearly UC-pattern distinguishable
from AR, whereas FNAC in these patients often shows patterns
indistinguishable from rejection.
Renal changes n cytomegalovirus infection. L. A. Castro, J. M. Gokel,
G. Thoenes, G. Frdsner, W. Land, G. If illebrand, and H. J. Gurland.
Medizinische Klinik 1, Klinikum Grosshadern, Pat hologisches Inst it Ut,
Medizinische Klinik Innenstadt, Max-v -Pettenkofer-Institut, Trans-
p(antationszcntrum, Klinikum Grosshadern, University of Munich,
Munich, Federal Republic of Germany. Renal biopsy was performed in
20 graft recipients to characterize the histological features associated
with poor renal function concomitant with cytomegalovirus infection
(CMV). Eight patients presented with proteinuria, three had microscop-
ic hematunia at onset, and five had hypertension. Onset of infection was
accompanied by clinical syndrome (fever, leukopenia, mild hepatic
damage, or pneumonitis) in 15 patients. In all serum creatinine was > 2
mgldl. Seven patients showed glomerular changes on biopsy, and
vascular changes were the predominant feature in seven patients.
Immunofluonescence demonstrated 1gM and C3 complement in glomer-
uli from five of six patients. Serum creatinine remained below 2 mg/dl at
10 to 26 months following the infectious episode in four patients. In
seven patients creatinine levels were between 2 to 3 mg/dl at 14 to 24
months, while nine developed irreversible rejection and endstage renal
failure. CMV is the most commonly recognized viral infection following
transplantation and can cause renal changes, both glomerular (CMV
glomerulopathy) and vascular (transplant vasculopathy), which may
induce poor graft function.
Be novo development of hypercholesterolemia and persistence of
hypoapoproteinemia in patients with chronic renal failure (CRF) follow-
ing kidney transplantation. N. Kobayashi, M. Okubo, and F. Marumo.
Department of Medicine, Kitasato University, School of Medicine,
Sagamihara, Japan. Serum lipids, apoprotein levels, and lecithin-
cholesterol acyltransferase activities were studied in 28 renal transplant
recipients with stable renal function sustained for more than a year
following grafting. Hypertriglycenidemia, which was characteristic of
hypenlipidemia of 18 hemodialyzed patients with CRF, was no longer
conspicuous in transplant recipients. On the other hand, hypercholes-
terolemia was observed in transplant recipients. As to the high density
lipoprotein profile, its cholesterol content was significantly higher in
transplant patients than that in hemodialyzed patients. In contrast,
apoprotein A-I was found to be similarly decreased below normal in
both groups of patients.
CRF on HD
(18)
Transplant recipients
I to 5 years
(12)
5 years <
(16)
TG, mmoles/liter
CHL, mmoleslljter
HDL-CHL, mmoleslliter
Apo A-I, glliter
LCAT, imoles/mlIhr
1.81 0.65a
4.80 1.17
0.89 0.33a
1.41 0.14
56 17
1.42 0.53
6.34 I.37'
1.82 0.56a
1.44
96
1.41 0.85
6.26 l.28a
1.51 0.56
0.15
22b
a p < 0.001, vs. normal control; ( ): number of patients.
P < 0.001, vs. CRF on HD.
TG, CHL, and HDL-CHL of the normal subjects were 1.23 0.41
(mean SD, N = 532), 5.39 0.95 (N = 575) and 1.45 0.28 (N = 313),
respectively. Thus, derangement in lipid metabolism, although qualita-
tively different, may continue to be present following transplantation.
T.Suppressor cell abnormalities in type 1 MPGN. B. Brando, G.
Busnach, S. Bertoli, M. L. Nova, and L. Minetti. Renal Unit, Ni-
guarda-Ca 'Granda Hospital, Milano, Italy. To investigate T-suppres-
sor cell (Ts) abnormalities, 12 patients with type I MPGN have been
studied. All had normal renal function, proteinuria less than 2 g/24 hr,
illness lasting 4 to 132 months. None under therapy. In 7 of 12 serum C3
andlor C4 were low. T-cell subsets were analyzed by monoclonal
antibodies of the OKT series. Ts function (T5F) was studied by the
ConA-Enhancement test (ConAE) and with a specially designed assay
where the response to Pokeweed mitogen is measured before and after
physical OKI8+ cell removal (PWM-OKT8). In Table 1 MPGN pa-
tients are considered all together. In Table 2 normo (N) and hypocom-
plementemics (H) are compared.
Table 1 OKT4/OKT8 % ConAE act. % PWM-OKT8 act.
Controls
MPGN (All)
1.86 0.72
1.29 0.50
P < 0.025
47.5 15
35.6 22
P n.s.
40.7 13.1
18.3 11.4
P < 0.005
Table 2 OKT4/OKT8 % ConAE act. % PWM-OKT8 act.
18.4 14.1
16.5 10
P n.s.
MPGN (N)
MPGN (H)
1.68 0.44
1.01 0.34
P < 0.01
31.3 20
35.9 25
P n.s.
The low OKT4/OKT8 ratio is related to an increase of OKT8+ cells (P
<0.05), while H patients also have a reduction in OKT4+ subset (P <
0.005). TsF as studied with ConAE test is unchanged, but PWM-OKT8
test enabled us to detect a highly significant defect in MPGN. Hypo-
complementemia may be a marker of this defect. An increased number
of poorly fqnctioning peripheral OKT8+ cells in type I MPGN is
postulated.
Minimal change glomerulonephritis (MCGN) and focal glomeruloscler-
osis (FGS): Markers and "in vitro" activity of peripheral mononuclear
cells (PBMC). P. Dall'Aglio, C. Chizzolini, and C. Brigati. immunolo-
gia Clinica, Clinica Medico e Nefrologia, Univesitd di Parma, Parma,
Italy. PBMC of eight patients (P) with idiopathic nephrotic syndrome
and low levels seric IgG (<600 mg%), four with MCGN and four with
FGS, were studied to analyze their immunologic activity. PBMC were
separated on Na-metrizoate-Ficoll gradient and the most common
markers: sheep red blood cells receptors (T cell), surface membrane Ig
(B cell) and receptors for Fe of IgG on T cells (T0) were identified. The
synthesis of DNA by PBMC cultured in the presence of the polyclonal
activators phytohemagglutinin (PHA) and pokeweed mitogen (PWM)
was also evaluated. The production of Ig by PBMC was estimated by
culturing 5 x 106 cells in the presence of PWM and determining the
amount of IgG, IgA, 1gM in the supernates by a solid phase immunoflu-
orescent assay (Immunofluor Bio-Rad). No differences were found
between P and 20 healthy controls, age- and sex-matched, in percentage
and absolute number of T and B cells, whereas an increased number of
TG (suppressor cell in the PWM driven system) was demonstrated in P.
The PBMC response to PWM was decreased in P both in terms of DNA
synthesis and IgG production, suggesting a defect in cellular cooper-
ation or an intrinsic B cell defect.
Morphologic and functional tubular changes in chronic glomerulone-
phritis (GN). M. Ratner, V. V. Serov, B. I. Rosenfeld, W. Sinn, R.
Schmicker and H. Klinkmann, institute of Transplantation and Art(fi-
cia! Organs, Moscow, SU, Department of Medicine, W. Pieck Univer-
sity, Rostock, German Democratic Republic. The importance of tubular
dysfunction in GN preceeding a decrease in glomerulofiltration rate
(GFR) has been supported by the morphologic finding of tubular
lesions. Interstitial sclerosis and atrophy of tubular cells labeled tubular
interstitial component (TIC) may be found in all varieties of GN and are
of prognostic value. This study investigated a possible correlation
between tubular dysfunction and morphological changes as related to
unimpaired GFR. In 135 patients (92 male, 43 female, avg. 32.3 years)
with different types of GN without impairment of GFR (CIN > 100 ml!
mm), biopsy specimens were studied with special attention to TIC.
Tubular function studies included: UOSM max, UOSM mm, CH,O, UNH4
+ V, UH+ V, Ta, and UNH4 + VIUH + V. Patients could be divided into
three groups according to morphologic changes: (1) severe TIC (45
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patients), (2) moderate TIC (56 patients), (3) no TIC (34 patients). In (1)
tubular function parameters were significantly decreased except for TA
and C+. In (2) CH2O and UOSM max only were significantly altered. In
(3) there were no significant functional changes. Where a combination
of decrease of UOSM max and CNH4 was present severe TIC was found
in all cases. In GN significant tubular dysfunction correlates with
tubular morphologic changes and can precede decrease in OFR. Severe
TIC is always seen in all patients exhibiting a combination of signifi-
cantly decreased UOSM max and CNH4.
Glomerular deposits of rheumatoid factor (RF) in glomerulonephritis
(GN). F. Bartolomeo, A. L'Abbate, C. Martorano, V. Misefari, A.
Caccamo, and Q. Maggiore. Centro di Fisiologia Clinica C.N.R.,
Reggio Calabria, italy. To assess the role of RF in immunologically
mediated GN, we looked for RF deposits in 140 renal biopsy specimens
obtained from 138 patients. Renal biopsies were classified as follows:
minimal glomerular changes 8, focal glomerulosclerosis 12, IgA
nephropathy 7, acute GN 15, intra- and extracapillary proliferative GN
(IEPGN) 6, membranous GN 9, membranoproliferative GN 7, chronic
liver disease with GN 11, lupus nephritis (SLE-GN) 17, essential mixed
cryoglobulinemia with GN (EMC-GN) 8, unclassified glomerular le-
sions (UGL) 19, other nephropathies 20. RF deposits in frozen tissue
sections were assessed with a preparation of fluoresceinated aggregated
IgG (FAIgG). RF deposits were found in one with UGL, six with acute
ON, two with IEPGN, four with SLE-GN, and seven with EMC-GN.
To identify the nature of RF deposits special studies were carried out on
kidney specimens from patients with EMC-GN. Evidence of RF
activity being sustained by 1gM deposits was based on (1) recovery of
monoclonal 1gM anti-IgG from the eluate of a kidney specimen, (2)
positive reaction of the RF deposits with alkylated and reduced FAIgG,
(3) specific blockade of FAIgG binding after treatment of tissue sections
with the unfluoresceinated anti-IgM serum. The results suggest that RF
partake in immunologically mediated glomerular damage of acute GN,
SLE-GN, and EMC-GN.
Isolated C3 in the "vascular pole" in patients with primary hematuria.
P. Barceló, A. Covarsi, J. A. BallarIn, J. L. Rodriguez, C. Gelpi, and
G. del Rio. FundaciOn Puigvert Universidad Autonoma de Barcelona,
Spain. Primary or nonurologic hematuria has been associated with
minor glomerular abnormalities and mesangial deposits of IgA, 1gM, or
isolated C3. We reviewed 81 renal biopsy specimens performed on
patients with primary hematuria (nonurologic diseases and absence of
proteinuria). In seven patients (11%) we observed the presence of C3 in
the "vascular pole" of the glomeruli associated to minimal increase of
mesangial matrix in light microscopy. In all patients serum immuno-
globulin levels (IgA, IgG and 1gM) were measured. Three patients with
minor lesions had high IgA levels (15%), 13 with Berger disease (58%);
one with 1gM mesangial (16%), and two with "vascular pole" (32%). An
increase of 1gM was seen in two patients with minor lesions (10%); four
had Berger disease (16%), two 1gM mesangial (32%), and nothing with
deposits of C3 in vascular pole. The serum complement levels (total-C;
Clq C3l C4) were normal in all patients and no abnormalities were
observed in cryoglobulins or immunocomplexes (polietilenglicol). Addi-
tionally, we have obtained by surgery seven specimens of normal
kidney (lithiasis, pole tumors, cysts) and in no patients we observed a
deposit of C'3 in the vascular pole. The follow-up of the seven patients
with C'3 in "vascular pole" was done between 20 to 41 months and
abnormalities persisted in five. No renal insufficiency, hypertensive, or
urologic disease was observed since biopsy. Conclusion: The so-called
primary hematuria is associated in 22% of the patients with deposits of
C'3 in vascular pole of glomeruli, and these patients have a good
prognosis.
Berger nephropathy (BN): Relationship between histologic pattern,
blood pressure (BP), and renin (PRA). E. Degli Esposti, P. Zucchelli, C.
Chiarini, A. Santoro, A. Sturani, A. Zuccala, L. Cagnoli, U. Donini,
and S. Pasquali. Divisione di Nefrologia e Dialisi—Osp. M. Malpighi,
Bologna, Italy. The relationship between vascular damage (VD),
glomerular sclerosis (GS) and BP was assessed in 50 patients (32
normotensive and 18 hypertensive) with biopsy-proven BN and normal
renal function. The previous parameters were also related to PRA and
plasma aldosterone (PA) in 34 of the 50 patients. OS was found in 62%
of the patients and was not related to VD: GS was present in five of 15
patients without VD and affected more than 15% of glomeruli in seven
patients with minimal VD. GS was not related to BP: Nine of 19 patients
with GS affecting more than 15% of glomeruli were normotensive. VD
was more frequent in hypertensive than in normotensive patients but
was often present in the normotensive group: Eighteen of 28 patients
with a VD grade Ito 2 were normotensive. Thus, hypertension does not
appear to be the only mechanism responsible for VD, and moreover,
GS is not related to VD. While hypertensive patients showed low-
normal PRA levels, seven normotensive patients (29%) had raised PRA
and PA levels. In the latter group GS was not present while VD was
absent in five and minimal in two patients. We conclude that in BN the
inflammatory lesion of the mesangium may affect the secretory function
of the juxtaglomerular apparatus and that the prolonged output of PRA
and PA could cause sustained hypertension.
Autogenous saphenous vein AV fistulas for hemodialysis: 8 years
experience with 30 patients. W. Lornoy, I. Becaus, J. P. Gillardin, J.
Cuvelier, M. Vermaut, P. Van Malderen, and G. Souffriau. Renal Unit,
0. L. Vrouwhospital, Aalst, Belgium. In 30 patients (mean age, 50
years), 41 autogenous saphenous veins (ASV) AV fistulas were created.
The vein was inserted 20 times in the forearm as a loop between the
brachial artery and a suitable vein in the anticubital region under
general anesthesia. Twenty-one ASV AV fistulas were created in the
thigh in a straight or loop manner subcutaneously with only one
anastomosis, that is, a side to end AV anastomosis with the superficial
femoral artery above the knee or the common femoral artery under
epidural anesthesia. All patients were dialyzed with the single needle
device using the double headpump, to ease controlling the high venous
back pressure of these fistulas. The present experience totals 1150
AS V-months with a mean useful life of 28 months. In 19 patients, this
fistula functions until now or until patients death with a mean of 42
months (2 to 97 months). Failure occurred in 22 ASV, mainly caused by
thrombosis. This was most often due to outflow stenosis in the forearm
and to inflow stenosis in the thigh. The blood flow ranged from 180 to
240 ml/min during hemodialysis. Symptoms of peripheral arterial insuf-
ficiency did not occur. We conclude that if a conventional AV fistula is
not feasible, an ASV fistula is the method of choice except in the few
patients with an ASV with an inappropriate diameter. With 8 years
experience, we now prefer the "straight" ASV fistula in the (right for
easier venipuncture) thigh. The advantages are the creation of only one
anastomosis under epidural anesthesia, a good patient tolerance, the
possibility for rapid use when necessary, its long viability in some
patients, and no supplementary costs.
Non-thrombotic complications of PTFE.grafts for hemodialysis. M. J.
H. Slooff, P. J. H. Smits, and G. K. van der Hem. University Hospital
Groningen, the Netherlands. In a series of 76 PTFE-grafts (37 Impra
and 39 Gore-tex) 29 complications were observed in 28 grafts (37%).
Only ten (13%) were lost. Hemorrhage (6) and formation of aneurysms
(10) were due to faulty puncture techniques. The incidence of these
complications (16) was more in Impra (12 of 16) than in Gore-tex grafts
(4 of 16). Only two of the six grafts with hemorrhage could be salvaged.
The other four grafts were lost because of longitudinal tears or multiple
close puncture holes. Eight of the ten grafts with aneurysms could be
saved by segment resections. Two grafts (Impra) were abandoned
because of multiple aneurysms. Skin erosions due to the graft were
observed in four patients. They were closed successfully by a bipedical
flap. Ischemia was seen in two grafts. Banding of the arterial anastomo-
sis was successful in both patients. Infection occurred in seven grafts
(9%). Three of these were lost because of massive bleeding from a
ruptured infected arterial anastomosis. The other infected grafts were
salvaged successfully by draining the infected site, with subsequent
reconstruction. From these observations it seems obvious that an
aggressive surgical approach to complications is followed by success in
most patients (18 of 28). As to the type of PTFE-graft, it seems clear
that the Impra graft is more prone to puncture lesions and aneurysm
formation than the Gore-tex graft.
Echothomography in arterio-venous fistulas. P. M. Ghezzi, A. Dutto,
F. Lupo, V. Grivet, P. Novara, R. Palanca, A. Rovere, G. Voile, and
G.' Cento (Introduced by G. Gurreri). S. Croce Hospital, Cuneo and
Martini Hospital, Torino, Italy. Morphological and functional study of
arteriovenous fistulas (AVF) for hemodialysis is at present rarely
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performed because the available methods employ contrast media or
radioisotopic tracers. Contrast media may cause local and/or systemic
reactions, while radioisotopic techniques do not show fine details.
Moreover, both cannot be repeated after a short period. To overcome
such limitations, we used Echothomography (by 2.25 to 5 MHz probes)
and a quick procedure was made ready. Such a method allows
measurement of the vessels' diameter at a definite point, to detect
aneurysms and their evolution, to evaluate the FAV wall characteris-
tics, and to make evident hematomas, thrombi, collateral ways. In
effect, the echothomography is a noninvasive technique, it may be
performed every time it is useful (even immediately after AVF surgery).
The most interesting results of 57 AVF were found in the examination
of proximal AVF and internal shunts (autologous venous graft, bovine
carotid). Echothomography has proven to be an accurate procedure to
study the AVF characteristics, in their initial morphological and func-
tional evaluation and their follow-up.
Influence of aluminium on parathyroid hormone levels in hemodialysis
patients. J. B. Cannata, J. D. Briggs, B. J. R. Junor, G. Beastall, and
G. S. Fell. Renal Unit, Western Infirmary, Glasgow, and University
Department of Pathological Biochemistry, Royal Infirmary, Glasgow,
Scotland. To investigate the relationship between parathyroid hormone
(PTH) and aluminium (Al), we measured serum Al, calcium (Ca)
phosphorus (P) and PTH in 86 patients (age range, 17 to 62 years) who
had all received hemodialysis three times weekly for longer than 6
months. The patients were separated into three groups according to
their serum PTH levels. Group 1: PTH < 600 ng/liter (29 patients,
normal PTH Group). Group 2: PTH 600 to 900 ng/liter (10 patients,
borderline PTH Group). Group 3: PTH > 900 ng/liter (47 patients, high
PTH Group). No significant differences were detected between groups
1, 2, and 3 regarding age, time on hemodialysis, aluminium hydroxide
intake, serum P, and drug therapy. A statistically significant difference
was found between groups 1 and 3 in the serum Al (P < 0.003) and
serum Ca (P < 0.0125) levels.
Serum Al
Group smoles/liter
I Normal PTH 4.85 0.68 2.43 0.04
2 Borderline PTH 3.48 0.55 2.40 0.04
3 High PTH 2.84 0.22 2.32 0.03
Our finding that the serum Ca was higher in the group with higher serum
Al and lower PTH levels suggests that Al can suppress PTH release
through an elevation of the serum Ca. However, a direct action of Al on
the parathyroid glands cannot be excluded.
Idiopathic hypercalcemia of chronic dialysis. T. G. Feest, D. J. Read,
and P. Newrick. Royal Devon and Exeter Hospital, Exeter, United
Kingdom. Johnson (1980) described three hemodialysis patients with
unexplained hypercalcemia apparently reversed by transplantation:
three similar patients, all females, from our 80 chronic dialysis patients,
were studied. Patient: (a) 53 years old, 15 months intermittent peritone-
al dialysis; (b) 41 years, 15 months hemodialysis, (c) 51 years, 22
months CAPD. Serum total calcium (3.45, 3.5, 3.1 mmoles/iter),
ionized calcium (1.58, 1.68, 1.59, upper normal 1.3 mmoles/liter), and
phosphate were raised, and serum parathyroid hormone, independently
checked in three laboratories, was at the lower limit of normal in all
three patients. We found no malignancy, myqloma, sarcoid, hyperthy-
roidism, excess calcium ingestion, or aluminium intoxication: Vitamin
D analogues had not been given. Skeletal surveys show severe decalci-
fication. There is no radiological or bone biopsy evidence of hyperpara-
thyroidism. Isotope bone scans were normal. Intestinal calcium47
absorption was abnormally low in all three patients, suggesting the
calcium comes from bone. Prednisolone suppressed serum calcium in
all patients, calcitonin did not. Patient (a) presented in acute hypercal-
cemic neurological crisis and 20 months later still needs 10 mg predniso-
lone daily to suppress hypercalcemia, which also persists in (b) and (c)
after 8 and 4 months. All have back pain from vertebral collapse. We
give steroids to suppress serum calcium hoping the benefits outweigh
the risk of osteoporosis. This idiopathic hypercalcemia syndrome of
chronic dialysis has significant clinical sequelae with severe skel&tal
decalcification, is unrelated to method of dialysis, and is steroid
suppressible.
Vibration sensory threshold—A simple guide to adequacy of dialysis?
D. J. Read, R. Holman, and T. G. Feest. Royal Devon and Exeter
Hospital, Exeter, United Kingdom. Vibration perception is the first
sensory modality diminished in uremic neuropathy: like other manifes-
tations of this condition, it has been difficult to measure. The Biothesio-
meter, an inexpensive machine producing vibration of constant fre-
quency and controllable amplitude, enables rapid non-invasive repro-
ducible bedside estimation of vibration sensory threshold (VST). We
have studied VST over 18 months in 53 chronic dialysis patients, 13
uremic patients, and 19 transplanted patients, and have compared
results with age- and sex-matched controls. VST was measured at four
sites, the mean of three readings at each site being used. VST does not
rise until plasma creatinine exceeds 800 moles/liter, but in 53 long-
term dialysis patients with no clinical signs of neuropathy VST was
significantly higher than controls (P < 0.001). A single dialysis does not
alter VST. VST was not related to acetylator status, serum creatinine,
aluminium, drug treatment, or type of dialysis. Patients dialyzed for less
than 1 year had a better VST than others, possibly due to residual renal
function: Thereafter, VST is not related to duration of dialysis. On
follow-up 1 year later most patients showed a small deterioration of
VST, although a few had improved following a change in the form of
dialysis. In 19 successfully transplanted patients VST was normal, a
marked difference from dialysis patients (P < 0.001). Sequential studies
in nine patients show VST returns to normal within 7 days of successful
transplantation. Measurement of VST is a quick reproducible test
which is abnormal in uremic patients and is rapidly reversed by return
of renal function. It may be a useful guide to adequacy of dialysis.
Ultrastructural (US) findings of the uremic muscular damage: Func-
tional implications. G. M. Savazzi, V. Cambi, and L. Migone. Depart-
ment of Medicine and Nephrology University, Parma, Italy. Ten
patients (P) in conservative treatment (CP) (creatininemia, 14 mg%) and
10 hemodialyzed patients (HP) (minimum, 71; maximum, 158 months)erum a
showing EMG tracings characterized by abnormal recruitment (all P)mmoles/liter fibrillation (7 P) polyphasism (17 P), reduced motor NCV in SPE (19 P)
and PT nerve (all P), complained early fadiguability (all P) and impor-
tant muscular hypotrophy (9 P). All P were submitted to sural nerve and
omolateral gastroonemius muscle biopsy. Specimens were fixed in 5%
glutaraldehyde, postfixed in 1% osmium tetroxide, and imbedded in
epoxiresins for US exam. Gastroonemius muscle surveys were charac-
terized by Z discs of adjacent myofibrils no longer arranged in register
and loss of myofilaments was replaced with amorphous material,
explaining muscular hypotrophy and reduced function. US sural nerve
findings of severe axonal damage were in agreement in the muscle with
regular repeating unit structures of sawtooth, tortuous sarcolemma,
indicative of secundary muscle compromise. In the extrafibrillar sarco-
plasm all P showed both qualitative (transverse reorientation, hypertro-
phy, hypercristae) and quantitative (hyperplasmia) mitochondrial
changes suggestive of disadvantageous energetic utilization. The loss of
contractile material was greater in the HP than in the CP group. In a CP
and 4 HP a totally occluded lumen of intramuscular capillary vessels
indicated components of chronic hypossy in the pathogenesis of the
uremic muscular damage.
Clinical implications of presence of refractile particles in liver of
hemodialysis patient. J. M. Morales, F. Colina, J. Arteaga, A. Barrien-
tos, V. G. Millet, L. M. Ruilope, J. M. Alcazar, andJ. L. Rodicio. CS.j0 de Octubre," Madrid, Spain. In a retrospective study we have
examined 16 liver specimens from patients in hemodialysis with a mean
time under treatment of 27 months. Nine were biopsy specimens from
patients with previous biochemical hepatic dysfunction. Seven were
necropsy specimens in patients without biochemical alterations. Five
out of the nine (55%) biopsies showed refractile particles in the liver
with the same appearance of that described elsewhere. In all the seven
specimens from patients without hepatic alterations the same particles
were found. This material was associated with the same degree of
fibrosis, inflammation, and granulomatous reaction. None of our pa-
tients could be diagnosed of cirrhosis from a pathological point of view.
We were unable to find statistical correlation between fibrosis or
inflammation with the amount of deposition of the refractile material.
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Furthermore there was no correlation between degree of deposition and
time on hemodialysis. We think of this deposition as a fortuitous finding
with uncertain clinical implications. The absence of biochemical hepatic
alterations in the necropsied patients and the absence of relation with
fibrosis and inflammation point this way.
Improvement of insulin binding to human erythrocyte insulin receptors
in uremia by hemodialysis. S. Milutinovié, D. Breyer, N. Jankovié, and
V. Molmac. Centre for Hemodialysis and Institute for Diabetes,
Zagreb, Yugoslavia. To investigate insulin resistance in uremia, specif-
ic insulin binding (IB) to erythrocytes (RBC) was determined using
radioreceptor assay. lB was reduced by 50% in 20 nondiabetic uremic
patients in comparison with 20 healthy controls (9.5 versus 4.7%, P <
0.05). During the 5-hr period of hemodialysis (MD) specific lB steadily
increased in a time dependent manner by 1.5% per hour in average
attaining at the ed of the treatment 90% of the value of healthy
controls. The increase in lB depended on efficiency of HD as assessed
by relative decrease of plasma urea, creatinine, or uric acid (P < 0.01).
Incubation of RBC of healthy donors with uremic plasma of the same
blood group decreased lB by about 40%, whereas incubation of uremic
RBC with plasma of healthy donors improved TB by about 30%.
Conclusion: Uremic plasma contains dialysis substances which revers-
ibly inhibit lB to erythrocyte insulin receptors.
Effects of hemodialysis on insulin requirements in uremic diabetic
patients. Studies with the artificial beta-cell. 0. Schmitz, A. P. Hansen,
H. E. Hansen, V. Posborg, H. Orskov, and K. G. M. M. Alberti. First
and Second University Clinic of Internal Medicine, Kommunehospita-
let, Aarhus, Denmark, and Department of Clinical Biochemistry and
Metabolic Medicine, University of Newcastle-upon-Tyne, United King-
dom. The majority of azotemic patients are characterized by having an
impaired carbohydrate metabolism which is mainly due to peripheral
tissue insensitivity to insulin of unknown Origin. The present study was
done to investigate the 24-hr insulin requirements in type 1 diabetic
uremic patients, using a glucose controlled insulin infusion system
(Biostator"). All patients (N = 5) were studied twice. Before (2 to 10
days) and after (28 to 48 days) was the initiation of chronic intermittent
hemodialysis. Diet was identical in the two situations. Mean age was 37
years (range, 29 to 42 years) and diabetes duration was 19, 15 to 25
years (mean, range). Predialysis/postdialysis: Serum urea was 36 6/13
1 (± 1 SEM) mmoles/liter (P < 0.05). The mean body weight was 68.8/
68.5 kg (NS). The total daily insulin consumption was reduced by 19%
after initiation of dialysis therapy (47.2 2.8 U versus 38.4 3.7 U, P
< 0.02). Furthermore, the mean 24-hr blood glucose was also signifi-
cantly lower after commencement of dialysis (5.5 0.1/5.2 0.1
mmoles/Iiter; P < 0.02). Theinsulin reduction concerned both the basal
as well as the post-prandial consumption. Plasma growth hormone did
not differ in the two situations; other counter-regulatory hormones and
relevant plasma intermediary metabolites are currently being analyzed.
pH-Dependence of phosphate absorption in rat renal proximal tubule.
I. Samarzija, V. Molnar, and E. Frömter. Center of Hemodialysis and
Nephrology and Institute of Pharmacology, Zagreb, Yugoslavia and
Max-Planck-Institute für Biophysik, Frankfurt, Federal Republic of
Germany. Hypercapnia decreases phosphate (P1) absorption in renal
proximal tubule. This observation was confirmed in micropuncture and
microperfusion studies but different explanations were given on the
basis of experiments with membrane vesicles: (1) exclusive absorption
of HP04 and (2) indiscriminate absorption of H2P04 and HP04
with decreasing vmax at low pH. To further elucidate the question we
have studied, whether the Na-dependent P,-absorption is associated
with the flow of electrical charge, and if so, how it depends on luminal
pH. Tubular cell membrane potentials were recorded in response to
adding 2.0 mmoles/liter of P, to Na Ringers solution. Allow pH (6.0)
the cells depolarized by 4.4 1.3 mV (N = 8) while at high pH (8.5)
they did not (0 0.4 mY, N = 11). Studying the response to P, as
function of pH steps of 0.6 U between pH 6.0 and 8.4, the depolariza-
tion was found to decrease gradually but less steeply than the concen-
tration of H2P04. The data support a model concept which holds (1)
that H2P04 and HP04 are absorbed in the same proportion in which
they are present in the lumen fluid, (2) that the Na/P coupling
stoichiometry is 2.0 so that the flow of H2P04 is positively rheogenic
while the flow of HP04 is electro-neutral and (3) that the maximal
transport capacity (vmax) of the transport system decreases with de-
creasing pH.
Control of hyperparathyroidism, hyperphosphatemia and hyperalu-
minemia in hemodialyzed patients by high doses of calcium carbonate. P.
Morinière, J. Sebert, L. Gregoire, M. C. Jaudon, Y. Tahiri, A. Roussel,
and A. Fournier. CHU Amiens and Pitié Paris, France. To assess the
prevalence of hyperaluminemia induced by Al(OH)3 and the possibility
to replace Al(OH)3 by high doses of CaCO3, plasma concentrations of
aluminium (Al), calcium (Ca), phosphate (P04), parathyroid hormone
(P'FH by N and C terminal assays) were measured before and after 6
months of Al(OH)3 discontinuation and progressive increase of oral
CaCO3 from 3 to 25 g/d, in 27 stable patients chronically dialyzed with a
water treated by reverse osmosis. Previously given vitamin D was also
discontinued. Because of diarrhea or persistent hyperphosphatemia the
trial was discontinuted in four patients.
Patients with vit D7)
Before 6 months
12 2
9.3 I
5.2 3*
38 7
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Three years' experience on the nutritional treatment of chronic uremia
with an artificial low protein diet supplemented with essential aminoacids
and ketoanalogues (ALPD). G. Barsotti, E. Morelli, F. Ciardella, A.
Giannoni, A. Guiducci, and S. Giovannetti. Clinica Medica I , Univer-
sity of Pisa, Italy. After a period on a conventional low protein diet
(CLPD) (supplying approximately 30 g of high biological value protein,
600 mg of phosphorus and 2.40 Kcal daily) 25 uremic patients were
submitted to an ALPD for 4 to 36 months. ALPD supplied about 12 g of
unselected proteins, 250 mg of phosphorus and the same amount of
Kcal, as the' CLPD. During CLPD creatinine clearance decreased
monthly by 0.71 0.42 ml/min, and during ALPD by 0.29 0.44 ml/
mm. Serum inorganic phosphorus decreased from 5.48 1.8 mg/dl to
4.8 0.94 mg/dl (P. < 0.01). Serum calcium increased from 8.5 0.8
mg/dl to 9.2 0.8 mg/dl (P < 0.01). Serum alkaline phosphatase
decreased to normal levels in the four patients who had previously high
values. In five patients studied the serum iPTH (N-terminal fragment)
fell from 0.51 0.27 ng/ml to 0.12 0.03 ng/ml (P < 0.05) and the C-
terminal fragment from 5.89 2.01 ng/ml to 2.73 0.42 ng/ml (P <
0.02). In 20 patients the N-terminal fragment was normal at the end of
ALPD (mean = 0.13 0.09 ng/ml). These data suggest that artificial
diet slows the rate of deterioration of renal function in uremia patients
and causes an improvement of the secondary hyperparathyroidism.
Al was above normal (40 ng/ml) in ten patients before Al(OH)3
discontinuation and in only two after. Metastatic calcifications devel-
oped in two patients in whom Ca x PD4 was above 700. Transient
hypercalcemia (>11 mg/dl) occurred in seven patients. Conclusions: (1)
Higher doses of CaCO3 maintained in most patients a good control of
hyperphosphatemia and hyperparathyroidism and a correction of hy-
peraluminemia. (2) Because of possible induction of metastatic calcifi-
cations and hypercalcemia, this treatment is recommended only in case
of hyperaluminemia and under close monitoring of PCa and P04.
Changes of cardiac weight and beta catecholaminergic responsiveness
in experimental uremia. M. Rambauser. Department of Internal Medi-
cine, University of Heidelberg, Heidelberg, West Germany. In previous
experiments, we found an enhanced a-adreno-receptor responsiveness
in acute uremia. We now report on beta receptor responsiveness in
acute uremia. Methods: Bilaterally nephrectomized rats (36 hr, acute
uremia) and sham-operated controls were investigated (N = 60).
Femoral arterial and venous catheters were placed (ether anesthesia).
Blood pressure (BP) and heart rate (HR) were measured in the
conscious rats via the arterial catheter. Autonomic reflexes and renin-
angiotensin system were inhibited with atropin, pentolinium, and the
angiotensin I converting enzyme inhibitor MK 421. After stabilization
Patients without vit D(16)
Results:
Mean SEM Before 6 months
CaCO3, gld 4 1 10
AI(OH)5, gld 4 I 0
Ca, mgldl 9.3 1.5 9.4 2
PO, mgld/ 4.9 3 4.8 3
Al, ng/ml 60 10 30
PTH C, nglml 392 60 360 50
PTFI N, ng/mI 0.21 0.05 0.18 0.05
P significance of the change: *<005, *n<O.
6
5
9.3 I
6.0 7
50 7
373
0.23 0.08
562 Abstracts
of BP and HR, isoproterenol was administered in cumulative doses
(0.001 to 5 pg/kg i.v.) Results: Baseline HR was reduced (P < 0.05) in
uremic rats. Maximal effect of isoproterenol in acute uremia on HR was
reduced (P < 0.01) without change in ED50. To exclude influences of
potassium or acidosis, rats were kept on a low potassium diet for 1 week
prior to nephrectomy and received sodium-bicarbonate. Again, in
normocalemic acute uremia (serum potassium: 4.5 0.3 mmoles/liter,
pH 7.41 0.02), a reduced maximal effect of isoproterenol on HF was
found (P < 0.01). Conclusion: Our results suggest opposite effects of
acute uremia on alpha- and beta-receptor-mediated actions, that is,
reduced beta and enhanced alpha-receptor responsiveness.
Prednisone-induced increase of proteinuria in patients with a nephrotic
syndrome. P. G. G. Gerlag, F. H. J. M. van Liebergen, and R. A. P.
Koene. Department of Medicine, Division of Nephrology, University of
Nmegen, The Netherlands. Administration of corticosteroids can lead
to an abrupt increase of proteinuria in patients with a nephrotic
syndrome. This paradoxical phenomenon was systematically studied in
nine patients with an epimembranous glomerulopathy, who received
125 to 150 mg of prednisone on alternate days in the course of a
therapeutic trial. Proteinuria on prednisone (P)- and nonprednisone
(NP)-days was studied during a period of 10 to 22 days. The mean
proteinuna for the whole group on NP-days was 43.6% lower than on P-
days and varied between individual patients from 0.4 to 78.9%. There
was a significant correlation with the endogenous creatinine clearance
(ECC): Fluctuations were larger when ECC was higher (r = 0.73, P <
0.05). In individual patients, however, there was neither differences in
24-hr creatinine excretions nor in ECC between P and NP days. The
proteinuric effect started 4 hr after an oral or intravenous prednisone
dose, was maximal between 8 and 16 hr, and had disappeared after 20
hr. The lowest dose of prednisone that induced the effect was 15 mg.
The phenomenon was also seen in patients with other causes of their
nephrotic syndrome. A patient with minimal change glomerulopathy
showed the fluctuations while reaching a remission. The effect may be
related to a temporary increase of glomerular filtration rate or a
decrease in tubular reabsorption of protein. Our failure to find concomi-
tant changes in ECC argues against the former explanation.
Plasmapheresis-induced recovery from renal failure in mesangiocapil-
lary glomerulonephritis of acute onset. J. Montoliu, E. Bergadá, A.
Botey, A Torras, A. Darnell, J. LOpez-Pedret, and L. Revert. Hospital
Clinic, Barcelona, Spain. Plasmapheresis (P) was performed in three
patients with severe renal failure due to mesangiocapillary glomerulone-
phntis (MCGN) of acute onset (clinical or laboratory evidence of renal
disease of less than 3 months' duration). Renal biopsy showed type II
MCGN in patient 1, also suffering from partial lipodistrophy, and type I
MCGN in patients 2 and 3. Extracapillary proliferation was present in
90, 40, and 60% of glomeruli in patients 1, 2, and 3, respectively. In each
patient, an average of 12.3 3 (SD) P sessions (4-liter exchange) were
performed over a period of less than 6 weeks. Prednisone 1 mg/kg/day
and cyclophosphamide 2 mg/kg/day were also given for 2 months.
Following P, serum creatinine decreased from a peak of 4.4 to 1.5 mg/dl
in patient 1 (a 66% reduction), from 5.6 to 2.2 mg/dl in patient 2 (a 61%
reduction) and from 13.6 to 2.4 mg/dl in patient 3 (an 82% reduction).
Patient 3 required dialysis temporarily. His lowest serum creatinine was
obtained when he had been off dialysis for a month. After completion of
P renal function remained stable for 7.5, and 2 months in patients 1, 2,
and 3, respectively. All of them continue to have proteinuria and
microscopic hematuria. P appears to facilitate recovery from renal
failure in MCGN of acute onset, possibly by removing circulating
mediators of acute inflammatory glomerular damage. Since spontane-
ous improvement in this form of glomerulopathy is rare, our results are
encouraging and further trials with P seem warranted.
Effect of thymus factor (TFX) and levamisole threatment in patients
with persistent nephrotic syndrome (NS). S. Czekalski, D. Sulima, and
C. Strezelecka. Academy of Medicine, Szczecin, Poland. T-lymphocyte
deficiency in immune complex glomerulonephritis (GN) and a disorder
of T-lymphocytes function in nephrotic syndrome have been reported.
The effect of two immunopotentiating agents: thymus factor (TFX-
Polfa, 10 mg iv. daily during 1 to 2 months) and levamisole (150 mg in
two consecutive days weekly during 1 to 2 months) on the clinical
picture and some indices of cellular immunity have been evaluated in
two comparable groups of five patients with persistent (at least 6
months) NS due to ordinary GN. All patients refused the immunosup-
pressive therapy and revealed decreased T-lymphocytes percent and
function. Diminution of proteinuria (range, 7 to 39% of initial value)
without a change in GFR, accompanied by an increase in E rosette
forming T-lymphocytes, increased responsiveness to PHA and normal-
ization of previously augmented percent of EA and EAC rosettes
forming lymphocytes, was observed in four patients treated with TFX
and only one patient treated with levamisole. In the remaining five
patients transient augmentation of proteinuria has been observed with-
out the effect on the other parameters. The results suggest that the
improvement of impaired T-lymphocyte function in patients with NS
treated with TFX was associated with a slight diminution of proteinuria,
while levamisole treatment was without beneficial effect.
Decreased number of a-adrenergic receptors in platelets of patients on
maintenance hemodialysis. O.-E. Brodde, A. Daul, and N. Graben.
Division of Renal and Hypertensive Diseases, Medizinische Klinik und
Poliklinik, University of Essen, Federal Republic of Germany. We have
recently shown that in human platelet membranes a2-adrenergic recep-
tors (a-R) can be identified by 3H-yohimbine binding. With this
technique we have determined the number of platelet a-R in 36 healthy
subjects (hs) of different ages (14 to 76 years) and in 33 patients on
maintenance hemodialysis (pmh, aged 24 to 69 years). In hs a highly
significant negative correlation (r = —0.666, P < 0.001) between the
number of a-R and age was found, while plasma catecholamines (CA)
increased with age. In pmh, on the contrary, such a correlation between
the number of a-R and age did not exist (r = —0.04, P > 0.1). There
was, however, a significant negative correlation between plasma CA
and the number of -R (r =
—0.602, P < 0.01). The affinity of 3H-
yohimbine to platelet a-R was in hs and pmh similar. The dissociation
constant (K0) amounted to 1 to 2 nM. The mean plasma CA in the
collective of pmh was significantly higher than that in hs, whereas the
mean number of cr-R was decreased in pmh. It is concluded that the
reduced number of a-R and/or the elevated plasma CA in pmh may play
an important role in regulating the responsiveness of the sympathetic
nervous system to adrenergic stimuli.
The effects of diffusion and ultrafiltration on cardiac output and organ
blood flows. T. Kishimoto, K. Sugimura, T. Nakatani, S. Yamagami,
and M. Maekawa. (Introduced by S. Nakagawa). Osaka City Universi-
ty Medical School, Osaka, Japan. Hemodialysis (HD) therapy for
chronic renal failure is based on two processes: solute removal by
diffusive mass-transfer and fluid removal by ultrafiltration (UF). Symp-
tomatic hypotension and dialysis-induced disequilibrium syndrome are
major adverse reactions of HD. However, much higher fluid removal
rate was tolerated when ultrafiltration and diffusion were separated. We
studied the individual and combined influence of UF and diffusion on
cardiac output and organ blood flows. The following experiments were
performed on the bilateral nephrectomized dogs having the same BUN
level and fluid overload as HD patients. Cardiac output (CU) and organ
blood flow were measured by modified microsphere technique. Four
groups of dogs were studied by the following treatments: (1) 2-hr
extracorporeal circulation only; (2) 2-hr HD; (3) 2-hr HF; (4) 1-hr
diffusion followed by isolated UF. HD caused a decrease in CO and
mean blood pressure (MAP) without an increase in total peripheral
resistance (TPR). No change in hepatic arterial and cerebral blood flow
but decrease in other organs. In diffusive phase of sequential therapy, a
decrease in MAP and TPR despite no change in circulatory plasma
volume (CPV) and CU. In UF phase, MAP was recovered with an
increase in TPR despite the decrease in plasma volume and CO.
Muscular vascular resistance was reduced in the diffusive phase but
increased in UF phase. The results suggest that symptomatic hypoten-
sion is the result of the decrease in CPV through UF and the effect of
diffusion impairing cardiovascular compensation mechanism.
Left ventricular function during hemofiltration (HF) and hemodialysis
(lID): A comparative study. P. Alfama, A. Martin-Malo, R. Sanz, J.
Pasalodos, M. Sancho, E. Moreno, J. Gomez, R. Perez, and L. G.
Burdiel. C. S. "Reina Sofia," University of Cordoba, Spain. Although
systemic hemodynamics during HF and HD have been investigated
widely, comparative cardiac function studies are lacking. We have
therefore dissociated the consequences of solute transport from the
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effects of replacement buffer on myocardial performance. Controlled
echocardiograms were conducted in five groups of ten stable patients
with normal cardiac function parameters and similar weight loss during:
HF with acetate (Ac), HF with lactate (La), HD with Ac, HD with
bicarbonate (Bi) and sequential ultrafiltration-diffusion. Measurements
included: (a) Systemic hemodynamics by mean arterial pressure(MAP), cardiac index (Cl) and vascular resistance (VR); (b) whole
ventricular function by ejection fraction (EF); (c) myocardial contract-
ibility by velocity of circumferential fiber shortening (VCF), and
exponential rate of fiber shortening (ERFS). Main results (%):
MAP CI VR EF VCF ERFS
HF-Ac 3 —l6 +24* +1 +3 +4
HF-La 4 -l8' +21* +2 +2 +3
HD-Ac +2 _22* 3 —1 +1
HD-Bi —2 9* +4 +17* +29* +25*
* = P < 0.05
Comparable changes to HF and HD occurred during ultrafiltration and
diffusion, respectively. We conclude that convective transport, inde-
pendently of replacement buffer, involves just an increase in VR with
no changes in ventricular performance. In contrast, diffusive transport
induces different effects in relation to the dialysate buffer: Ac decreases
VR and Bi significantly improves myocardial contractibility shifting the
cardiac function curve to the left.
Controlled trial of 1,25 dihydroxycholecakiferol in prevention of bone
disease in hemodialysis patients. V. L. Sharman, S. M. L. Abrams, S.
Adami, W. R. Cattell, R. N. Greenwood, F. J. Goodwin, W. Hately, F.
P. Marsh, A. G. Morgan, J. W. Muir, J. O'Riordan, S. E. Papapoulos,
P. Revel!, D. M. Chaput de Saintonge, A. K. Tucker, and L. R. I.
Baker. The London and St. Bartholomew's Hospitals, London, United
Kingdom. We report a 5-year double-blind, placebo controlled trial of
1 ,25(OH)3D3 in the prevention of bone disease in hemodialysis patients.
Seventy-eight patients with normal serum calcium, alkaline phospha-
tase, and skeletal radiographs were allocated to 1 ,25(OH)2D3 or placebo
groups as described previously. Dialysate calcium concentration was
1.65 mmoles/liter. Source water aluminum concentrations were low.
Assessment was by measurement of serum alkaline phosphatase and by
annual skeletal x-rays. One microgram I ,25(OH)2D3 daily regularly
induced hypercalcemia (serum calcium >2.75 mmoles/liter). With doses
between 0.25 g twice weekly and 0.5 .rg daily, hypercalcemia was
infrequent. Significantly more patients on placebo developed bone
disease as judged by a sustained elevation of serum alkaline phospha-
tase concentration (16 vs. 6, P < 0.02). The serum PTH (C-terminal
assay) concentration was significantly lower on 1 ,25(OH)2D1 than on
placebo. Prophylactic 1 ,25(OH)2D3 inhibits the development of meta-
bolic bone disease in hemodialysis patients. The place of routine
prophylaxis will be discussed.
Parathyroid (PT) ultrasonography (US) and fine-needle aspiration
biopsy in the diagnosis of secondary hyperparathyroidism. L. Solbiati, A.
Giangrande, G. Montali, C. Ravetto. General Hospital, Busto Arsizio,
Italy. Early treatment of secondary hyperparathyroidism may some-
times raise therapeutic problems, mainly when bone histology is not
available, because discrepancies between biochemical abnormalities
and x-ray lesions are often noted. In 68 uremic patients, on hemodialy-
sis from 42 to 164 months (: 87 40) and presenting with questionable
clinical findings, PT US was performed as complementary diagnostic
investigation, using a commercially available B-scanner. In 21 patients
(29%), PT hyperplasias were detected; in 11 patients, two or more
hyperplastic glands were demonstrated in the same patient. Hyperplas-
tic PT glands appeared as echopoor lesions whose diameters ranged
between 0.8 and 2.5 cm. When their location within the neck was
atypical (mainly intrathyroideal) or their echopattern was uncommon
(cystic-like lesions, that is), US guided fine needle aspiration biopsy
was performed. In nine of ten patients cytological examination of
aspirated material could confirm the presence of PT cells. US detection
of large PT hyperplasias sometimes confirmed by cytology can be very
useful in the choice of the best treatment.
Quantitative assessment of carnitine loss during hemodialysis and
hemofiltration. K. W. Rumpf, M. Leschke, T. Eisenhauer, K. Becker,
U. KOthe, and F. Scheler. Department of Nephrologv, University
Hospital, Gottingen, Federal Republic of Germany. Carnitine deficien-
cy has been claimed to be responsible for the myo- and cardiomyopathy
observed in dialysis patients and has been attributed to the loss of
carnitine during dialysis. To quantitate carnitine loss during dialysis and
hemofiltration, carnitine concentrations were determined by a radioen-
zymatic method in 23 patients on chronic hemodialysis and ten patients
on chronic hemofiltration treatment. Measurements were performed in
serum, hemofiltrate, and urine. Mean serum concentrations in terminal
renal failure patients averaging 39.9 2.7 imoles/liter (x SEM) were
significantly lower (P < 0.001) than in healthy controls (49.0 2.0
.rmoles/liter; N = 43). Hemodialysis and hemofiltration led to a further
reduction of serum carnitine levels (33.1 3.5, imoles/liter; P <
0.001). Hemofiltration treatment resulted in a loss of 795 84 imoles
carnitine/week. This was not significantly different from urinary carni-
tine excretion in healthy controls (1071 169 smoles/week). It is
concluded that carnitine deficiency in dialysis patients cannot only be
explained by losses into dialysate or filtrate. Other factors such as
reduced endogenous carnitine synthesis, decreased alimentary carni-
tine intake or defective intestinal carnitine reabsorption must be in-
volved. Preliminary studies, however, demonstrate that the latter factor
does not seem to be of importance, since after an oral load of L-carnitine
in four dialysis patients serum carnitine levels increased similarly to
normal control subjects.
Endocrine-metabolic effects of L-carnitine in patients on regular dialy-
sis treatment (RDT). A. Albertozzi, P. Cappelli, B. Di Paolo, and P.
Pola. Nephrology and Dialysis Department, University of Chieti,
Chieti, Italy. The fall in plasma carnitine during dialysis induces a
progressive tissue depletion contributing to hypertriglyceridemia and
muscle weakness. Twenty-three patients on RDT were given L-carni-
tine orally (1 g/day, 12 patients) or in dialysis (100 moles/liter, II
patients) for 6 months. At the start, at 2, 4, and 6 months we
determined: biochemistry (residual GRF, BUN, creatinine, uric acid,
Na, K, Ca, P, alkaline phosphatase, SGOT-SGPT, glucose, blood
count), lipid pattern (triglycerides, total and VLDL-LDL-HDL choles-
terol, Apo A, Apo B, atherogenic risk index), hormonal pattern (PTH,
insulin, C-peptide, glucagon, somatostatin, GH) serum L-carnitine, and
acetyl-carnitine. Orally supplemented patients underwent muscle biop-
sy for histology-histochemistry and assay of muscle carnitine and
acetyl-carnitine basally and at 6 months. All patients remained in a
stable biochemical state with a slight increase in PCV; hyperlipidemia
(type IV 8, ha 2, JIb 6) was reduced with an increase in HDL; Apo A
also increased while Apo B decreased. Hormonal pattern was unmodi-
fied (high PTH, insulin, C-peptide, glucagon; normal GH and somato-
statin). Serum and muscle carnitine and acetyl-carnitine constantly
increased. No patient experienced any side-effects; (80% reported a
sense of well-being and increased muscle-strength. L-carnitine in RDT,
by restoring tissue reserves, improves metabolic alterations without
any side effects.
Reduction of elevated plasma oxalic acid levels by pyridoxine therapy in
patientsonRDT. P. Balcke, P. Schmidt, J. Zazgornik, andH. Kopsa. I.
Medical Clinic, Vienna, Austria. Increased plasma oxalic acid levels
(Pox) seem to be an important factor for calcium oxalate deposits often
observed by pathologists in patients on RDT. As administration of
pyridoxine has been reported to diminish synthesis of oxalic acid in
some patients suffering from primary hyperoxaluria, it was of interest,
whether a similar effect could also be observed in patients on RDT with
secondary hyperoxalemia due to accumulation of oxalic acid. In eight
patients on RDT pyridoxine was given (300 mg orally daily or 600 mg
intravenously after each dialysis). Mean Pox decreased from 149.5
76.0 to 99.0 36.4 mmoles/liter within 2 weeks and to 93.8 33.1
mmoles/liter after 4 weeks of pyridoxine treatment (normal values II .2
6.2 mmoles/liter). Mean reduction was 46(32 to 56.1) percent. T-test
for all paired samples was highly significant for both periods (P <
0.001). The decline of Pox was pronounced in patients with high plasma
concentrations and protracted in patients with lower initial levels. Two
patients just on pyridoxine therapy since some months before the start
of our study revealed low initial values and no further decrease. The
effect of pyridoxine was independent of the mode of application. High
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dose pyridoxine therapy resulting in a decrease of elevated Pox in
patients on RDT could be a therapeutic approach to prevent uremic
calcium oxalate deposits.
Association between rising hemoglobin concentration and renal cyst
formation in patients on long-term regular dialysis treatment. H. J.
Goldsmith, R. Ahmad, N. Raichura, 0. H. B. Gyde, S. M. Lal, D. A.
Gould, and C. A. McConnell. Renal Unit, Royal Liverpool Hospital,
Liverpool, United Kingdom. Patients on regular dialysis treatment(RDT) are known to develop cysts in their kidneys. Our clinical
observation that patients who were on RDT in excess of 10 years were
no longer seriously anemic was tested by reviewing our 20 RDT patients
(13 male, 7 female; mean age, 44.8 years), whose duration of dialysis
was 6 to 13 years. Measured 24-hr urine volumes and plasma erythr-
poietin concentration (mouse liver cell assay) did not correlate with
hemoglobin concentration (Hb). Kidney size (length >< depth), cyst
size, and the extent of cyst formation were independently measured by
two radiologists using "Aloka" real time ultrasound apd "Diasono-
graph" B scanner. Renal cysts were detected in 17 of 20(85%) of these
patients. We observed that the Hb of all our seven RDT patients (DD x
10.7 years) rose from X 7.4 g/dl st 0.81 over the first 3 years toX 11.1
gIdI sn 1.63 over the last 3 years (P < 0.005), and kidney size
averaged 63.9 U. In seven patients on RDT (DD X 6.4 years) there was
no observed significant change of Hb concentration X 9.1 g/dl SD 3.81
to 9.0 g/dl SD 3.02 (P < 0.3) and the kidney size averaged 40.8 U. In
the remaining six patients (DD X 7.0 years) in whom the Hb fell from
7.4 g/dl SD 0.23 to 6.3 g/dl SD 0.48 (P < 0.005), the kidney size
averaged only 30 U. We conclude that rising Hb values in long-term
RDT patients are associated with increasing kidney size and/or cyst
formation.
Dopamine-furosemide therapy in acute renal failure (ARF). G. Gra-
ziani, S. Casati, A. Canta/uppi, A. Citterro, A. Aroldi, D. Brancaccio,
and C. Ponticelli. Dialysis Unit, Policlinico and S. Paolo Hospital,
Milan, Italy. Experimental studies show that in hypoperfused kidney,
dopamine in low doses stimulates specific intrarenal receptors, produc-
ing cortical vasodilation; on the other hand, furosemide induces vasodi-
lating prostaglandin synthesis. Consequently, an association between
these two drugs seems to be a rational approach for prevention of
oliguria. In 16 ARF patients (15 postoperative, I postpartum) and in
three hepatorenal syndrome in whom mannitol and high-dose furose-
mide failed to promote diuresis, we infused dopamine in subpharmaco-
logical dose (3 jg/kg/min) and furosemide (10 to 15 mg/kg/hr) for 6 to 24
hr. This treatment produced in all patients a significant increase of
diuresis (from 12.2 8.8 to 100.4 28.1 mi/hr P < 0.001) and of
natriuresis (from 30.5 13.2 to 81.8 27.4 mEq/liter P < 0.001)
without any modification of blood pressure, pulse rate, and central
venous pressure. No side effects were observed. Five out of 16 patients
required dialysis, despite polyuria, four died for causes unrelated to
ARF. In three patients with hepatorenal syndrome diuresis was re-
stored during dopamine and furosemide infusion, but severe oliguria
again reappeared when drug infusion was stopped. This experience
suggests that this therapy may avoid fluid overload and hyperkalemia in
oliguric patients reducing the need for dialysis. It is also the first
successful approach in the treatment of hepatorenal syndrome although
its effect is transient.
Factor VIII, related antigen, coagulation test and acute renal failure. J.
Sampol, A. Robert, F. Jahjah, A. Gillet, and M. Olmer. Service de
Nephrologie, Laboratoire d'Hematologie, Hôpital de Ia Conception,
Marseille, France. Fifty patients with acute renal failure (ARF) admit-
ted in our unit had coagulation tests on admission day (Jl) and 7 days
later (J7) including: platelet counts, fibrinogen, kaolin cephalin clotting
time, prothrombin rate, alpha-2-antiplasmin (a2 AP), alpha-2-macro-
globulin (a2 macro G), alpha-l-antitrypsin (a! AT), Cl inhibitor (Cl I),
antithrombin III (AT 3), plasminogen (PG), factor VIII coagulant
activity (VIII C), factor VIII related antigen (VIII Ag). Results: on JI,
platelet count was normal except in nine patients in whom it was below
100 000 mm3, and out of these patients, there was only one patient of
disseminated intravascular coagulation: a2 AP and AT 3 decreased, a2
macro G, al AT and mainly VIII Ag increased. The patients were
classified in two groups and compared according to the evolution of the
disease: patients who are still alive (A: 22 patients), patients who died
(B: 28 patients). The average age was 57.4 7.4 in group A and 64 4.5
in group B. On Jl, PG was considerably lowered in group B (P < 0.001)
as well as AT 3 (P < 0.05). On J7, in the eight patients who died later on,
PG remained low (P < 0.05) and factor VIII Ag was very high while it
was normal in group A (P < 0.001), the difference was significant.
Conclusion: A PG decrease and a marked increase of VIII Ag, which
suggests a damage of the endothelial tissue rather than coagulation
disorders, are considered as elements of poor prognosis in ARF.
Continuous hemofiltration maintains fluid balance and reduces hemo-
dialysis requirement in acute renal failure. N. J. Dodd, J. H. Turney, V.
Parsons, and M. J. Weston. King's College Hospital, London, En-
gland. We have used the Amicon 20S diafilter to provide continuous
arterio venous hemofiltration (CAVH) during the oliguric phase of
acute renal failure of ten patients, thus providing a preselected variable
fluid output and allowing adequate nutrition. Access to the circulation
was via scribner A-V shunts, heparinized via the inflow line to the
device at 500 to 750 U/hr producing very little systemic effect. Mean
blood flow rate was 35 mI/mm producing an ultrafiltrate rate of up to 10
ml/min to correct fluid overload which was then reduced to an average
of 3.5 mI/mm (5 liters/day). Intravenous fluid replacement consisted of
50% nutrition and 50% twice normal saline to maintain sodium balance.
This treatment reduced the frequency that hemodialysis was required
from daily to once every three days (approximately). Urea and creati-
nine clearance rates on CAVH were the same as the ultrafiltration rate.
The system was well tolerated, had no effect on blood pressure, and
produced no changes in platelet and neutrophil counts, or arterial P0,.
This treatment is effective, makes less demands on the time of hemodi-
alysis staff and may improve the management and prognosis of acute
renal failure.
Respiratory response of acetate dialysis and bicarbonate dialysis. A.
Solvadeo, G. Pezzagno, S. Segagni, F. Galli, G. Villa, V. Piazza, L.
Bovio, L. Picardi, F. Poggio, E. Petrilla, and L. Bigi. Nephrology and
Dialysis Department; Fondaz. Clinica del Lavoro, Pavia; Bellco Labo-
ratories, Mirandola, Italy. The reduction in arterial 02 pressure (Pa02)
described during acetate dialysis has been attributed to embolism of
pulmonary capillaries by neutrophils or to CO2 loss in the dialyzers. To
clarify these mechanisms we monitored pulmonary (spirometry/blood
gases) and acid-base parameters in nine patients undergoing 4-h single
pass dialysis with dialysate containing 38 mEq/liter acetate (AD) or with
31 mEq/liter HC03 plus 10 mEq/liter acetate (BD). During AD in the
first hour there is a reduction (P < 0.05) of external ventilation (VE)
alveolar ventilation (VA), CO2 ventilation (Vo,) and respiratory quo-
tient (RQ). In the second hour, V0 and VA return to the baseline values
while Vo, and RQ remain low. Oxygen consumption (V0,) and PaO2
do not change significantly. Arterial CO2 pressure (Pa02) decreases by
the second hour of dialysis (P < 0.05). During the first hour there is a
reduction of HCO3 (P < 0.05). There is a loss of 170 mM/hr across the
dialyzer in the form of HCO3 (160 mM/hr). In BD there is a gain of 25
mM/hr across the dialyzer. Neither pulmonary nor acid-base parameters
change. Conclusion: Hypoventilation is consequent to HC03 loss
during the first hour of dialysis and it disappears with the regeneration
of HC03 by acetate. The persistence of lower Vo, and RQ values is
caused by a reduction of Pco2 and HCO3 in mixed venous blood by
continuous loss of CO2 across the dialyzer.
No relationship between acetate and hypotension (HY) in a standard
dialysis schedule. A. Castellani, F. Lonati, G. Bigi, S. Bassi, F. Brand,,
M. Minari, andP. Poiatti. Nephrology and Dialysis Service, Umbertol
Hospital, Brescia, Bellco Laboratories, Mirandola, Italy. In an attempt
to elucidate the relationship between acetate and dialysis HY, plasma
acetate (PA) values were analyzed with a gas chromatographic method
during two regular dialysis treatment (RDT) sessions in 20 uremic
patients subdivided in two groups: a first of nine patients who had
presented hypotensive episodes during former RDT sessions with a
frequency ranging from 20 to 95%, and a second group of 11 patients
who had never experienced HY during former RDT sessions. PA was
analyzed in the two groups at t 060120', 180' 240' and in the first group
also 10' after each HY. Seven hypotensives were then switched to
bicarbonate-dialysis (BD) for up to 10 months. O, 00, dialysis hours
0.8 to 1 m2 standard membranes, dialyzers, dialysate Na (140 mmoles/
liter) were the same as in RDT. PA kinetics was stable for each patient.
Abstracts 565
PA peaks had a wide range (1.6 to 6.8 mmoles/liter) from patient to
patient. Correlations were not observed either between PA peaks and
intradialysis BP.A, or between PA peaks and number of HY. No
significant differences in PA kinetics were detected between groups.
Sharp increases of PA were never observed before and seldom ob-
served after HY. HY rates did not differ between BD and RDT (41.9 vs.
46.8% a 1.6 pns). It was concluded that intradialysis HY is not acetate-
dependent in a standard dialysis schedule and that BD in this regard is
not useful.
Side effects in bicarbonate dialysis due to low dialysate PH. L. Wagner,
B. Schindler, W. Marhoffer, 0. van Eyl, and M. Strauch. Clinic of
Nephrology, Klinikum Mannheim, University of Heidelberg, Mann-
heim, Federal Republic of Germany. Six commercially available con-
centrates for dialysis containing different amounts of bicarbonate (final
concentration 25 to 40 mval/liter) were compared with regard to their
acute effects on dialysis treatment (N = 2.0). With four concentrates
(pH 7.35 to 7.60, Pco2 25 to 65 mm Hg) Pco2 of blood remained in the
normal range during dialysis treatment (35 to 45 mm Hg). Blood pH
increased continuously up to normal values (7.35 to 7.50). With two
concentrates (pH 7.0 to 7.3, Pco2 60 to 130 mm Hg) patient response
was different: In nearly 90% of treatments with these concentrates
patients seemed to be able to eliminate high amounts of CO2 via
respiration even if the dialysate Pco2 increased beyond 100 mg Hg. In
10% of treatments blood pH of the arterial line decreased immediately
after the start of dialysis in varying degrees in some instances below 7.0,
blood Pco2 increased up to 100 mg Hg. Somnolence, headaches and
muscle cramps were observed as corresponding side effects. These
symptoms may be interpreted as beginning C02-narcosis, generated by
bicarbonate containing dialysate if blood Pco2 increases sharply due to
the low dialysate pH of certain commercially available concentrates.
Therefore the control of dialysate pH and Pco2 is mandatory in
bicarbonate dialysis.
Comparative EEG investigations during acetate (HDA) and bicarbon-
ate dialysis (HDB). H. Hampl, J. Klopp, R. Schiller, A. Pustelnik, M.
Wolfgruber, F. Hanefeld, and M. Kessel. Free University Department
of Nephrology and Pediatric Neurology, Berlin, Germany. Continuous
long-time EEG monitoring was performed on five patients with an
ambulatory Oxford-Medilog 4-channel EEG system, during HDA and
HDB, and every 30 mm arterial blood gases were measured. Visual
evaluation followed by meansof a display unit. EEG sections of interest
were printed on a standard EEG writer. During HDA the basic activity
was irregular: Slow thetaldelta waves and high voltage rhythmic
discharges were monitored concomitant with a significant (P < 0.0005)
decrease of arterial PaCO2 below 30 mm Hg. With the beginning of
hypocapnia EEG disturbances occurred and preceded the first symp-
toms of the disequilibrium (dis). In contrast, during (HDB) with a
normalization of PaCO2 normal EEG basic activity was registered
during the whole treatment and no dis occurred. There is a strong
correlation between changes in arterial PaCO2 and the cerebral blood
flow. A decrease of PaCO2 results in a rapid decrease of the cerebral
blood flow and an increase in the vessels of cerebral resistance. The fact
that the cerebral circulation mainly depends on metabolic factors
supports our hypothesis that the unsatisfactory correction of metabolic
acidosis, especially the decrease of PaCO2, may be responsible for the
occurrence of EEG disturbances and clinical signs of dis (HDA). The
lack of EEG changes during HDB, in the same patients, strengthened
this supposition.
Computer modelling of hemodialysis/ultrafiltration explaining the
pathogenesis of the dysequilibrium syndrome (DES). S. G. Dawids, and
A. H. Caspersen. University Hospital, Department P, Copenhagen,
Technical University of Denmark, Copenhagen, Denmark. Efficient
hemodialysis frequently gives rise to DES which may be correlated to
rapid corrections of pH, Nat, osmotic concentration, and so forth, in
the blood with subsequent shifts of solutes and water between body
compartments. With a 14-compartment simulation model on a new type
of hybrid computer system (Modular Symbolic Electronic Simulator,
MOSES), a dynamic analysis has been made of the fluid shifts and the
hemodynamic consequences. This analysis is based on data from 11
steady-state HD patients determining diffusion coefficients, fluid
spaces, and hemodynamic parameters ad modum SwanGanz®. The
model reactions correlate remarkably well with the clinical findings and
indicate quantitatively how far the hemodynamic compensatory mecha-
nisms can prevent circulatory collapse and hypovolemia, mainly by
lowering the mean capillary pressure. During steady weight dialysis, the
blood volume was reduced to approximately 65% before a sudden drop
in blood pressure occurred leading to accelerated volume reduction.
Dialysis-induced fluid shifts were much more pronounced than those
occurring during rapid ultrafiltration (2 liters/hr) to normal weight.
Brain edema would generally progress until 10 to 30 mm after dialysis.
It is concluded that the model is a useful tool for the tailoring of
individual dialysis strategies. It has proven to be a valuable method for
analysis of complex hypothesis and to design subsequent physiological
experiments.
Potassium (K) removal as a factor limiting the correction of acidosis
during dialysis (HD). B. Redaelli, S. Sforzini, G. Bonoldi, D. Limido, M.
R. Vigano, and F. Mascia (Introduced by F. Locatelli). Divisione
Nefrolagia Dialisi Ospedale Monza, Monza, Italy. During HD the fall
in extracellular K induces a predictable and rapid increase in K
intracellular/K extracellular ratio (increase in passive electrical mem-
brane potential), which may provoke an electrical hydrogen ion (H) flux
toward the intracellular space (ICS) in contrast to the chemical H flux
from ICS, so reducing the net H flux from ICS to the extracellular space
(ECS). The aim of this study was to evaluate whether this fact was a
factor limiting the correction of acidosis. Each of seven patients was
submitted three times to two different procedures (1) with dialysate
containing 2.0 mEq/Iiter of K(K02) and(2) with K free dialysate (K0O);
bicarbonate (Bic) was 34 mEq/liter constant. The diffusional fluxes
across the dialytic membrane (external balance) were obtained by
collecting the effluent dialysate hourly; the diffusional fluxes across the
cell membrane (internal balance) were calculated by the Sargent and
Gotch equation assuming as ECS half the urea distribution volume.
During K02-HD a mean of 242.1 mEq of Bic are added to the body; of
these 184.7 (76.3%) disappear from ECS due to neutralization of H
mostly released from the cellular buffers. During K00-HD only 176.8
mEq of Bic are taken from dialysate and only 78.5 of them (44.4%)
disappear from ECS. The internal and external balances of Bic were
significantly higher during K02-HD compared to K00-HD (P < 0.01 for
both). There is a significant negative correlation between K and Bic
both in external balances (P < 0.001) and in internal balances (P <
0.02). Our results completely agree with the hypothesis.
